Skip to main content
What types of page to search?

Alternatively use our A-Z index.

Em P Richard Clark
MA, MD, MRCP, FRCPath

Contact

R.E.Clark@liverpool.ac.uk

+44 (0)151 706 4323

+44 (0)151 794 9818

Publications

What type of publication do you want to show?

2024

Predicting treatment-free remission outcomes in Chronic Myeloid Leukemia patients using an integrated model of tumor-immune dynamics

DOI
10.1101/2024.10.10.617526
Preprint

2023

P503: A RANDOMISED TRIAL OF MOLECULAR MONITORING VERSUS STANDARD CLINICAL CARE IN YOUNGER ADULTS WITH ACUTE MYELOID LEUKAEMIA: RESULTS FROM THE UK NCRI AML17 AND AML19 STUDIES

Potter, N., Jovanovic, J., Ivey, A., Thomas, A., Wilhelm-Benartzi, C., Gilkes, A., . . . Dillon, R. (n.d.). P503: A RANDOMISED TRIAL OF MOLECULAR MONITORING VERSUS STANDARD CLINICAL CARE IN YOUNGER ADULTS WITH ACUTE MYELOID LEUKAEMIA: RESULTS FROM THE UK NCRI AML17 AND AML19 STUDIES. HemaSphere, 7(S3), e345570d. doi:10.1097/01.hs9.0000968920.34557.0d

DOI
10.1097/01.hs9.0000968920.34557.0d
Journal article

Generic imatinib: Data from the UK National Registry for chronic myeloid leukaemia patients

Nesr, G., Braithwaite, B., Mathew, P., Hashmi, M., Claudiani, S., Milojkovic, D., . . . Clark, R. E. (2023). Generic imatinib: Data from the UK National Registry for chronic myeloid leukaemia patients. In BRITISH JOURNAL OF HAEMATOLOGY Vol. 201 (pp. 92-93). Retrieved from https://www.webofscience.com/

Conference Paper

2022

Digital Droplet (dd) Polymerase Chain Reaction (PCR) Assays Offer Limited Advantages over Conventional Reverse-Transcriptase Quantitative PCR (RT-qPCR) for the Prediction of Molecular Recurrence after Treatment Discontinuation in Chronic Myeloid Leukemia (CML): Results from the Destiny Study

Dominy, K., Salmon, M., Szydlo, R., Hayden, C., White, H. E., Alikian, M., . . . Apperley, J. F. (2022). Digital Droplet (dd) Polymerase Chain Reaction (PCR) Assays Offer Limited Advantages over Conventional Reverse-Transcriptase Quantitative PCR (RT-qPCR) for the Prediction of Molecular Recurrence after Treatment Discontinuation in Chronic Myeloid Leukemia (CML): Results from the Destiny Study. In BLOOD Vol. 140 (pp. 9631-9632). doi:10.1182/blood-2022-170375

DOI
10.1182/blood-2022-170375
Conference Paper

Modelling of immune response in chronic myeloid leukemia patients suggests potential for treatment reduction prior to cessation

DOI
10.21203/rs.3.rs-1917622/v1
Preprint

A retrospective observational research study to describe the real-world use of bosutinib in patients with chronic myeloid leukemia in the United Kingdom and the Netherlands

Claudiani, S., Janssen, J. J. W. M., Byrne, J., Smith, G., Blijlevens, N., Raghavan, M., . . . Apperley, J. F. (2022). A retrospective observational research study to describe the real-world use of bosutinib in patients with chronic myeloid leukemia in the United Kingdom and the Netherlands. EUROPEAN JOURNAL OF HAEMATOLOGY, 109(1), 90-99. doi:10.1111/ejh.13775

DOI
10.1111/ejh.13775
Journal article

Outcomes of older patients aged 60 to 70 years undergoing reduced intensity transplant for acute myeloblastic leukemia: results of the NCRI acute myeloid leukemia 16 trial

Russell, N. H., Hills, R. K., Thomas, A., Thomas, I., Kjeldsen, L., Dennis, M., . . . Burnett, A. K. (2022). Outcomes of older patients aged 60 to 70 years undergoing reduced intensity transplant for acute myeloblastic leukemia: results of the NCRI acute myeloid leukemia 16 trial. HAEMATOLOGICA, 107(7), 1518-1527. doi:10.3324/haematol.2021.279010

DOI
10.3324/haematol.2021.279010
Journal article

Modelling of immune response in chronic myeloid leukemia patients suggests potential for treatment reduction prior to cessation

DOI
10.1101/2022.06.28.22277004
Preprint

P691: MODELLING OF IMMUNE RESPONSE IN CHRONIC MYELOID LEUKEMIA PATIENTS SUGGESTS POTENTIAL FOR TREATMENT REDUCTION PRIOR TO CESSATION

Karg, E., Baldow, C., Zerjatke, T., Clark, R. E., Roeder, I., Fassoni, A. C., & Glauche, I. (n.d.). P691: MODELLING OF IMMUNE RESPONSE IN CHRONIC MYELOID LEUKEMIA PATIENTS SUGGESTS POTENTIAL FOR TREATMENT REDUCTION PRIOR TO CESSATION. HemaSphere, 6, 586-587. doi:10.1097/01.hs9.0000845648.71966.87

DOI
10.1097/01.hs9.0000845648.71966.87
Journal article

P713: REAL-WORLD MANAGEMENT OF PATIENTS WITH CHRONIC MYELOID LEUKAEMIA (CML): FIRST ANALYSIS FROM THE UK NATIONAL REGISTRY FOR CML

Nesr, G., Szydlo, R., Braithwaite, B., Frackelton, S., Mathew, P., Hashmi, M., . . . Clark, R. E. (n.d.). P713: REAL-WORLD MANAGEMENT OF PATIENTS WITH CHRONIC MYELOID LEUKAEMIA (CML): FIRST ANALYSIS FROM THE UK NATIONAL REGISTRY FOR CML. HemaSphere, 6, 608-609. doi:10.1097/01.hs9.0000845736.31547.3f

DOI
10.1097/01.hs9.0000845736.31547.3f
Journal article

A randomised comparison of FLAG-Ida versus daunorubicin combined with clofarabine in relapsed or refractory acute myeloid leukaemia: Results from the UK NCRI AML17 trial

Russell, N. H., Hills, R. K., Kjeldsen, L., Clark, R. E., Ali, S., Cahalin, P., . . . Burnett, A. K. (2022). A randomised comparison of FLAG-Ida versus daunorubicin combined with clofarabine in relapsed or refractory acute myeloid leukaemia: Results from the UK NCRI AML17 trial. BRITISH JOURNAL OF HAEMATOLOGY. doi:10.1111/bjh.18195

DOI
10.1111/bjh.18195
Journal article

The UK SPIRIT 1 trial in newly diagnosed chronic myeloid leukaemia

Gallipoli, P., Clark, R. E., Byrne, J., Apperley, J. F., Milojkovic, D., Foroni, L., . . . O'Brien, S. (2022). The UK SPIRIT 1 trial in newly diagnosed chronic myeloid leukaemia. BRITISH JOURNAL OF HAEMATOLOGY, 196(6), E55-E57. doi:10.1111/bjh.17961

DOI
10.1111/bjh.17961
Journal article

Ponatinib with fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor chemotherapy for patients with blast-phase chronic myeloid leukaemia (MATCHPOINT): a single-arm, multicentre, phase 1/2 trial

Copland, M., Slade, D., McIlroy, G., Horne, G., Byrne, J. L., Rothwell, K., . . . Yap, C. (2022). Ponatinib with fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor chemotherapy for patients with blast-phase chronic myeloid leukaemia (MATCHPOINT): a single-arm, multicentre, phase 1/2 trial. LANCET HAEMATOLOGY, 9(2), E121-E132. doi:10.1016/S2352-3026(21)00370-7

DOI
10.1016/S2352-3026(21)00370-7
Journal article

2021

Ponatinib in Combination with FLAG-IDA Chemotherapy for Blast -Phase Chronic Myeloid Leukemia: Final Results of the Seamless Phase I/II Dose -Finding UK Trials Acceleration Programme (TAP) Matchpoint Trial

Copland, M., Slade, D., McIlroy, G., Horne, G., Byrn, J., Rothwell, K., . . . Yap, C. (2021). Ponatinib in Combination with FLAG-IDA Chemotherapy for Blast -Phase Chronic Myeloid Leukemia: Final Results of the Seamless Phase I/II Dose -Finding UK Trials Acceleration Programme (TAP) Matchpoint Trial. In BLOOD Vol. 138. doi:10.1182/blood-2021-147972

DOI
10.1182/blood-2021-147972
Conference Paper

A randomised evaluation of low-dose cytosine arabinoside (ara-C) plus tosedostat versus low-dose ara-C in older patients with acute myeloid leukaemia: results of the LI-1 trial

Dennis, M., Burnett, A., Hills, R., Thomas, I., Ariti, C., Severinsen, M. T., . . . Russell, N. (2021). A randomised evaluation of low-dose cytosine arabinoside (ara-C) plus tosedostat versus low-dose ara-C in older patients with acute myeloid leukaemia: results of the LI-1 trial. BRITISH JOURNAL OF HAEMATOLOGY, 194(2), 298-308. doi:10.1111/bjh.17501

DOI
10.1111/bjh.17501
Journal article

Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis (vol 35, 20-LEU-1554R, 2021)

Kantarjian, H. M., Hughes, T. P., Larson, R. A., Kim, D. -W., Issaragrisil, S., le Coutre, P., . . . Hochhaus, A. (2021). Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis (vol 35, 20-LEU-1554R, 2021). LEUKEMIA, 35(7), 2142-2143. doi:10.1038/s41375-021-01306-1

DOI
10.1038/s41375-021-01306-1
Journal article

Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis

Kantarjian, H. M., Hughes, T. P., Larson, R. A., Kim, D. -W., Issaragrisil, S., le Coutre, P., . . . Hochhaus, A. (n.d.). Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia. doi:10.1038/s41375-020-01111-2

DOI
10.1038/s41375-020-01111-2
Journal article

Real-world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: the UK TARGET CML study

Milojkovic, D., Cross, N. C. P., Ali, S., Byrne, J., Campbell, G., Dignan, F. L., . . . Mead, A. J. (2021). Real-world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: the UK TARGET CML study. BRITISH JOURNAL OF HAEMATOLOGY, 192(1), 62-74. doi:10.1111/bjh.16733

DOI
10.1111/bjh.16733
Journal article

2020

Defining the Optimal Total Number of Chemotherapy Courses in Younger Patients With Acute Myeloid Leukemia: A Comparison of Three Versus Four Courses.

Burnett, A. K., Russell, N. H., Hills, R. K., Knapper, S., Freeman, S., Huntly, B., . . . Spearing, R. (2020). Defining the Optimal Total Number of Chemotherapy Courses in Younger Patients With Acute Myeloid Leukemia: A Comparison of Three Versus Four Courses.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, JCO2001170. doi:10.1200/jco.20.01170

DOI
10.1200/jco.20.01170
Journal article

Selection and management of older patients with acute myeloid leukemia treated with glasdegib plus low-dose cytarabine: expert panel review

Cortes, J. E., Candoni, A., Clark, R. E., Leber, B., Montesinos, P., Vyas, P., . . . Heuser, M. (2020). Selection and management of older patients with acute myeloid leukemia treated with glasdegib plus low-dose cytarabine: expert panel review. Leukemia and Lymphoma, 61(14), 3287-3305. doi:10.1080/10428194.2020.1817445

DOI
10.1080/10428194.2020.1817445
Journal article

Bosutinib (BOS) Versus Imatinib for Newly Diagnosed Chronic Phase (CP) Chronic Myeloid Leukemia (CML): Final 5-Year Results from the Bfore Trial

Brümmendorf, T. H., Cortes, J. E., Milojkovic, D., Gambacorti-Passerini, C., Clark, R. E., le Coutre, P. D., . . . Deininger, M. W. (2020). Bosutinib (BOS) Versus Imatinib for Newly Diagnosed Chronic Phase (CP) Chronic Myeloid Leukemia (CML): Final 5-Year Results from the Bfore Trial. Blood, 136(Supplement 1), 41-42. doi:10.1182/blood-2020-137393

DOI
10.1182/blood-2020-137393
Journal article

Discovery of NOvel CIP2A VAriant (NOCIVA) and its clinical relevance in myeloid leukemias

DOI
10.1101/2020.08.24.264606
Preprint

Another set of guidelines for chronic myeloid leukaemia

Clark, R. E. (2020). Another set of guidelines for chronic myeloid leukaemia. British Journal of Haematology. doi:10.1111/bjh.16970

DOI
10.1111/bjh.16970
Journal article

A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease

Horne, G. A., Stobo, J., Kelly, C., Mukhopadhyay, A., Latif, A. L., Dixon-Hughes, J., . . . Copland, M. (2020). A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease. LEUKEMIA, 34(7), 1775-1786. doi:10.1038/s41375-019-0700-9

DOI
10.1038/s41375-019-0700-9
Journal article

Correction: CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy.

Kinstrie, R., Horne, G. A., Morrison, H., Irvine, D., Munje, C., Castañeda, E. G., . . . Copland, M. (2020). Correction: CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy.. Leukemia, 34(7), 1975. doi:10.1038/s41375-020-0721-4

DOI
10.1038/s41375-020-0721-4
Journal article

CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy

Kinstrie, R., Horne, G. A., Morrison, H., Irvine, D., Munje, C., Castaneda, E. G., . . . Copland, M. (2020). CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy. LEUKEMIA, 34(6), 1613-1625. doi:10.1038/s41375-019-0684-5

DOI
10.1038/s41375-019-0684-5
Journal article

Loss or Inhibition of Stromal-Derived PlGF Prolongs Survival of Mice with Imatinib-Resistant Bcr-Abl1<sup>+</sup> Leukemia.

Schmidt, T., Kharabi Masouleh, B., Loges, S., Cauwenberghs, S., Fraisl, P., Maes, C., . . . Carmeliet, P. (2020). Loss or Inhibition of Stromal-Derived PlGF Prolongs Survival of Mice with Imatinib-Resistant Bcr-Abl1<sup>+</sup> Leukemia.. Cancer cell, 37(1), 135-136. doi:10.1016/j.ccell.2019.12.010

DOI
10.1016/j.ccell.2019.12.010
Journal article

2019

FLAG-IDA and Ponatinib in Patients with Blast Phase Chronic Myeloid Leukaemia: Results from the Phase I/II UK Trials Acceleration Programme Matchpoint Trial

Copland, M., Slade, D., Byrne, J., Brock, K., De Lavallade, H., Craddock, C., . . . Yap, C. (2019). FLAG-IDA and Ponatinib in Patients with Blast Phase Chronic Myeloid Leukaemia: Results from the Phase I/II UK Trials Acceleration Programme Matchpoint Trial. In BLOOD Vol. 134. doi:10.1182/blood-2019-125591

DOI
10.1182/blood-2019-125591
Conference Paper

Introducing a Predictive Score for Successful Treatment Free Remission in Chronic Myeloid Leukemia (CML)

Claudiani, S., Metelli, S., Kamvar, R., Szydlo, R., Khan, A., Byrne, J., . . . Apperley, J. F. (2019). Introducing a Predictive Score for Successful Treatment Free Remission in Chronic Myeloid Leukemia (CML). BLOOD, 134. doi:10.1182/blood-2019-131500

DOI
10.1182/blood-2019-131500
Journal article

Long-Term Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving Frontline Nilotinib Versus Imatinib: Enestnd 10-Year Analysis

Hughes, T. P., Saglio, G., Larson, R. A., Kantarjian, H. M., Kim, D. -W., Issaragrisil, S., . . . Hochhaus, A. (2019). Long-Term Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving Frontline Nilotinib Versus Imatinib: Enestnd 10-Year Analysis. In BLOOD Vol. 134. doi:10.1182/blood-2019-128761

DOI
10.1182/blood-2019-128761
Conference Paper

Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin

Lauseker, M., Bachl, K., Turkina, A., Faber, E., Prejzner, W., Olsson-Stromberg, U., . . . Pfirrmann, M. (2019). Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin. AMERICAN JOURNAL OF HEMATOLOGY, 94(11), 1236-1243. doi:10.1002/ajh.25628

DOI
10.1002/ajh.25628
Journal article

Cardiac, vascular, and hypertension safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the BFORE trial.

Cortes, J. E., Brummendorf, T. H., Gambacorti-Passerini, C., Clark, R. E., Leip, E., Viqueira, A., . . . Deininger, M. W. N. (2019). Cardiac, vascular, and hypertension safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the BFORE trial.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 37. Retrieved from https://www.webofscience.com/

Conference Paper

Cancerous inhibitor of protein phosphatase 2A (CIP2A) modifies energy metabolism via 5′ AMP-activated protein kinase signalling in malignant cells

Austin, J. A., Jenkins, R. E., Austin, G. M., Glenn, M. A., Dunn, K., Scott, L., . . . Clark, R. E. (2019). Cancerous inhibitor of protein phosphatase 2A (CIP2A) modifies energy metabolism via 5′ AMP-activated protein kinase signalling in malignant cells. BIOCHEMICAL JOURNAL, 476, 2255-2269. doi:10.1042/BCJ20190121

DOI
10.1042/BCJ20190121
Journal article

De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial

Clark, R. E., Polydoros, F., Apperley, J. F., Milojkovic, D., Rothwell, K., Pocock, C., . . . Copland, M. (2019). De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial. The Lancet Haematology, 6(7), E375-E383. doi:10.1016/S2352-3026(19)30094-8

DOI
10.1016/S2352-3026(19)30094-8
Journal article

Nilotinib-induced metabolic dysfunction: insights from a translational study using in vitro adipocyte models and patient cohorts

Sadiq, S., Owen, E., Foster, T., Knight, K., Wang, L., Pirmohamed, M., . . . Pushpakom, S. (2019). Nilotinib-induced metabolic dysfunction: insights from a translational study using in vitro adipocyte models and patient cohorts. Leukemia, 33, 1810-1814. doi:10.1038/s41375-018-0337-0

DOI
10.1038/s41375-018-0337-0
Journal article

PF413 CARDIAC, VASCULAR, AND HYPERTENSION SAFETY OF BOSUTINIB VS IMATINIB FOR NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN THE BFORE TRIAL

Brümmendorf, T. H., Gambacorti‐Passerini, C., Clark, R., Leip, E., Viqueira, A., Kota, V., . . . Cortes, J. E. (2019). PF413 CARDIAC, VASCULAR, AND HYPERTENSION SAFETY OF BOSUTINIB VS IMATINIB FOR NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN THE BFORE TRIAL. HemaSphere, 3(S1), 159. doi:10.1097/01.hs9.0000559864.90626.f7

DOI
10.1097/01.hs9.0000559864.90626.f7
Journal article

PS1167 INDIVIDUAL RESPONSE OF CML PATIENTS TO TKI DOSE REDUCTION CAN RELIABLY IDENTIFY PATIENTS WITH HIGH RISK OF MOLECULAR RELAPSE AFTER TREATMENT CESSATION

Gottschalk, A., Glauche, I., Clark, R., & Röder, I. (2019). PS1167 INDIVIDUAL RESPONSE OF CML PATIENTS TO TKI DOSE REDUCTION CAN RELIABLY IDENTIFY PATIENTS WITH HIGH RISK OF MOLECULAR RELAPSE AFTER TREATMENT CESSATION. HemaSphere, 3(S1), 530. doi:10.1097/01.hs9.0000562952.20361.f0

DOI
10.1097/01.hs9.0000562952.20361.f0
Journal article

PS1182 REAL WORLD TYROSINE KINASE INHIBITOR TREATMENT PATHWAYS, MONITORING PATTERNS AND RESPONSES COMPARED WITH ELN RECOMMENDATIONS IN CHRONIC MYELOID LEUKAEMIA: FINAL ANALYSIS OF THE UK TARGET CML STUDY

Milojkovic, D., Cross, N. C., Ali, S., Byrne, J. L., Campbell, G., Dignan, F. L., . . . Mead, A. (2019). PS1182 REAL WORLD TYROSINE KINASE INHIBITOR TREATMENT PATHWAYS, MONITORING PATTERNS AND RESPONSES COMPARED WITH ELN RECOMMENDATIONS IN CHRONIC MYELOID LEUKAEMIA: FINAL ANALYSIS OF THE UK TARGET CML STUDY. HemaSphere, 3(S1), 538-539. doi:10.1097/01.hs9.0000563012.60265.ad

DOI
10.1097/01.hs9.0000563012.60265.ad
Journal article

Cardiac, vascular, and hypertension safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the BFORE trial.

Cortes, J. E., Brümmendorf, T. H., Gambacorti-Passerini, C., Clark, R. E., Leip, E., Viqueira, A., . . . Deininger, M. W. N. (2019). Cardiac, vascular, and hypertension safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the BFORE trial.. Journal of Clinical Oncology, 37(15_suppl), 7051. doi:10.1200/jco.2019.37.15_suppl.7051

DOI
10.1200/jco.2019.37.15_suppl.7051
Journal article

The effect on lymphocyte subsets of decreasing/stopping tyrosine kinase inhibitor therapy in chronic myeloid leukaemia: data from the DESTINY trial

Austin, G. M., Knight, K., Bell, J., Carter, A., Heartin, E., Watson, D., . . . Clark, R. E. (2019). The effect on lymphocyte subsets of decreasing/stopping tyrosine kinase inhibitor therapy in chronic myeloid leukaemia: data from the DESTINY trial. BRITISH JOURNAL OF HAEMATOLOGY, 185(4), 791-793. doi:10.1111/bjh.15629

DOI
10.1111/bjh.15629
Journal article

Long-term survival of CML patients who received autologous HCT before and after the tyrosine kinase inhibitors ERA. Study on behalf of the EBMT CMWP

Michallet, M., Sobh, M., Hazelaar, S., Apperley, J., Milpied, N., Labussiere-Wallet, H., . . . Yakoub-Agha, I. (2019). Long-term survival of CML patients who received autologous HCT before and after the tyrosine kinase inhibitors ERA. Study on behalf of the EBMT CMWP. In BONE MARROW TRANSPLANTATION Vol. 54 (pp. 201-202). Retrieved from https://www.webofscience.com/

Conference Paper

2018

DNA-Based Digital PCR for the Quantification of Residual Disease in CML - Sensitivity or Specificity?

Alikian, M., Ellwood, R., Tatarinova, O., Rose, G. D., Nteliopoulos, G., Gerrard, G., . . . Apperley, J. (2018). DNA-Based Digital PCR for the Quantification of Residual Disease in CML - Sensitivity or Specificity?. In BLOOD Vol. 132. doi:10.1182/blood-2018-99-117616

DOI
10.1182/blood-2018-99-117616
Conference Paper

Spirit 2: Final 5 Year Analysis of the UK National Cancer Research Institute Randomized Study Comparing Imatinib with Dasatinib in Patients with Newly Diagnosed Chronic Phase CML

O'Brien, S., Cork, L., Bandeira, V., Bescoby, R., Foroni, L., Alaily, L., . . . Clark, R. (2018). Spirit 2: Final 5 Year Analysis of the UK National Cancer Research Institute Randomized Study Comparing Imatinib with Dasatinib in Patients with Newly Diagnosed Chronic Phase CML. In BLOOD Vol. 132. doi:10.1182/blood-2018-99-110128

DOI
10.1182/blood-2018-99-110128
Conference Paper

Addition of the mammalian target of rapamycin inhibitor, everolimus, to consolidation therapy in acute myeloid leukemia: experience from the UK NCRI AML17 trial

Burnett, A. K., Das Gupta, E., Knapper, S., Khwaja, A., Sweeney, M., Kjeldsen, L., . . . Russel, N. H. (2018). Addition of the mammalian target of rapamycin inhibitor, everolimus, to consolidation therapy in acute myeloid leukemia: experience from the UK NCRI AML17 trial. HAEMATOLOGICA, 103(10), 1654-1661. doi:10.3324/haematol.2018.189514

DOI
10.3324/haematol.2018.189514
Journal article

Attenuated arsenic trioxide plus ATRA therapy for newly diagnosed and relapsed APL: long-term follow-up of the AML17 trial.

Russell, N., Burnett, A., Hills, R., Betteridge, S., Dennis, M., Jovanovic, J., . . . NCRI AML Working Group. (2018). Attenuated arsenic trioxide plus ATRA therapy for newly diagnosed and relapsed APL: long-term follow-up of the AML17 trial.. Blood, 132(13), 1452-1454. doi:10.1182/blood-2018-05-851824

DOI
10.1182/blood-2018-05-851824
Journal article

De-escalation and discontinuation of tyrosine kinase inhibitor treatment in chronic myeloid leukaemia (CML) in stable major molecular response: 2-year data from the British DESTINY study

Clark, R. E., Polydoros, F., Apperley, J. F., Milojkovic, D., Pocock, C., Smith, G., . . . Copland, M. (2018). De-escalation and discontinuation of tyrosine kinase inhibitor treatment in chronic myeloid leukaemia (CML) in stable major molecular response: 2-year data from the British DESTINY study. In BRITISH JOURNAL OF HAEMATOLOGY Vol. 181 (pp. 6). Retrieved from https://www.webofscience.com/

Conference Paper

Efficacy and Safety of First-Line Bosutinib versus Imatinib in the BFORE trial: 18-Month Follow-up

Clark, R. E., Gambacorti-Passerini, C., Deininger, M., Mauro, M. J., Chuah, C., Kim, D. -W., . . . Cortes, J. E. (2018). Efficacy and Safety of First-Line Bosutinib versus Imatinib in the BFORE trial: 18-Month Follow-up. In BRITISH JOURNAL OF HAEMATOLOGY Vol. 181 (pp. 7-8). Retrieved from https://www.webofscience.com/

Conference Paper

First report from the UK National Registry for chronic myeloid leukaemia: Analysis of baseline characteristics of 435 patients

Nesr, G. N. G., Szydlo, R., Braithwaite, B., Frackleton, S., Apperley, J., Milojkovic, D., . . . Clark, R. E. (2018). First report from the UK National Registry for chronic myeloid leukaemia: Analysis of baseline characteristics of 435 patients. In BRITISH JOURNAL OF HAEMATOLOGY Vol. 181 (pp. 48). Retrieved from https://www.webofscience.com/

Conference Paper

In chronic myeloid leukaemia cells, the oncoprotein CIP2A binds directly to and alters expression of many cellular proteins, independent of effects on protein phosphatase 2A (PP2A)

Austin, J. A., Lucas, C. M., Jenkins, R. E., Dunn, K., Scott, L. J., Glenn, M. A., . . . Clark, R. E. (2018). In chronic myeloid leukaemia cells, the oncoprotein CIP2A binds directly to and alters expression of many cellular proteins, independent of effects on protein phosphatase 2A (PP2A). In BRITISH JOURNAL OF HAEMATOLOGY Vol. 181 (pp. 52-53). Retrieved from https://www.webofscience.com/

Conference Paper

Snížení terapeutické dávky TKI před kompletním vysazením léčby zlepšuje šanci na úspěšné zastavení léčby u pacientů s chronickou myeloidní leukemií (CML): dvouleté výsledky britské studie DESTINY

Clark, R., Polydoros, F., Apperley, J., & Koblihová, P. J. (2018). Snížení terapeutické dávky TKI před kompletním vysazením léčby zlepšuje šanci na úspěšné zastavení léčby u pacientů s chronickou myeloidní leukemií (CML): dvouleté výsledky britské studie DESTINY. Transfuze a Hematologie Dnes, 24(1), 60.

Journal article

2017

E14a2 BCR-ABL1 transcript is associated with a higher rate of treatment-free remission in individuals with chronic myeloid leukemia after stopping tyrosine kinase inhibitor therapy

Claudiani, S., Apperley, J. F., Gale, R. P., Clark, R., Szydlo, R., Deplano, S., . . . Milojkovic, D. (2017). E14a2 <i>BCR-ABL1</i> transcript is associated with a higher rate of treatment-free remission in individuals with chronic myeloid leukemia after stopping tyrosine kinase inhibitor therapy.. Haematologica, 102(8), e297-e299. doi:10.3324/haematol.2017.168740

DOI
10.3324/haematol.2017.168740
Journal article

De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial

Clark, R. E., Polydoros, F., Apperley, J. F., Milojkovic, D., Pocock, C., Smith, G., . . . Copland, M. (2017). De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial. The Lancet Haematology, 4(7), E310-E316. doi:10.1016/S2352-3026(17)30066-2

DOI
10.1016/S2352-3026(17)30066-2
Journal article

Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitor-Sensitive and -Resistant Chronic Myeloid Leukemia

Ben-Batalla, I., Erdmann, R., Jorgensen, H., Mitchell, R., Ernst, T., Von Amsberg, G., . . . Loges, S. (2017). Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitor-Sensitive and -Resistant Chronic Myeloid Leukemia. CLINICAL CANCER RESEARCH, 23(9), 2289-2300. doi:10.1158/1078-0432.CCR-16-1930

DOI
10.1158/1078-0432.CCR-16-1930
Journal article

Cardiologist's perspective to the European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia Reply

Steegmann, J. L., Baccarani, M., & Clark, R. E. (2017). Cardiologist's perspective to the European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia Reply. LEUKEMIA, 31(3), 772-773. doi:10.1038/leu.2016.337

DOI
10.1038/leu.2016.337
Journal article

Treatment and outcome of 2904 CML patients from the EUTOS population-based registry.

Hoffmann, V. S., Baccarani, M., Hasford, J., Castagnetti, F., Di Raimondo, F., Casado, L. F., . . . Hehlmann, R. (2017). Treatment and outcome of 2904 CML patients from the EUTOS population-based registry.. Leukemia, 31(3), 593-601. doi:10.1038/leu.2016.246

DOI
10.1038/leu.2016.246
Journal article

2016

Chronic Myeloid Leukaemia Patients with Stable Molecular Responses (at least MR3) May Safely Decrease the Dose of Their Tyrosine Kinase Inhibitor: Data from the British Destiny Study

Clark, R. E., Polydoros, F., Apperley, J. F., Pocock, C., Smith, G., Byrne, J. L., . . . Copland, M. (2016). Chronic Myeloid Leukaemia Patients with Stable Molecular Responses (at least MR3) May Safely Decrease the Dose of Their Tyrosine Kinase Inhibitor: Data from the British Destiny Study. In BLOOD Vol. 128. doi:10.1182/blood.V128.22.938.938

Conference Paper

An operational definition of primary refractory acute myeloid leukemia allowing early identification of patients who may benefit from allogeneic stem cell transplantation

Ferguson, P., Hills, R. K., Grech, A., Betteridge, S., Kjeldsen, L., Dennis, M., . . . Craddock, C. (2016). An operational definition of primary refractory acute myeloid leukemia allowing early identification of patients who may benefit from allogeneic stem cell transplantation. HAEMATOLOGICA, 101(11), 1351-1358. doi:10.3324/haematol.2016.148825

DOI
10.3324/haematol.2016.148825
Journal article

CLONAL STRUCTURES OF LEUKAEMIA STEM CELL POPULATIONS IN MYELOID BLAST PHASE CHRONIC MYELOID LEUKAEMIA

Karamitros, D., Morrison, H., Kinstrie, R., Goardon, N., Clark, R. E., Copland, M., & Vyas, P. (2016). CLONAL STRUCTURES OF LEUKAEMIA STEM CELL POPULATIONS IN MYELOID BLAST PHASE CHRONIC MYELOID LEUKAEMIA. In HAEMATOLOGICA Vol. 101 (pp. 234-235). Retrieved from https://www.webofscience.com/

Conference Paper

THE ADVERSE EFFECTS OF CANCEROUS INHIBITOR OF PROTEIN PHOSPHATASE 2A, ARE LINKED WITH REDUCTION OF FUNCTIONAL B56GAMMA, A REGULATORY SUBUNIT OF PROTEIN PHOSPHATASE 2A, IN CHRONIC MYELOID LEUKAEMIA

Austin, J. A., Lucas, C. M., Scott, L., Holcroft, A., Wang, L., & Clark, R. E. (2016). THE ADVERSE EFFECTS OF CANCEROUS INHIBITOR OF PROTEIN PHOSPHATASE 2A, ARE LINKED WITH REDUCTION OF FUNCTIONAL B56GAMMA, A REGULATORY SUBUNIT OF PROTEIN PHOSPHATASE 2A, IN CHRONIC MYELOID LEUKAEMIA. In HAEMATOLOGICA Vol. 101 (pp. 182). Retrieved from https://www.webofscience.com/

Conference Paper

Defining The Dose Of Gemtuzumab Ozogamicin In Combination With Induction Chemotherapy In Acute Myeloid Leukemia: A Comparison Of 3 Mg/M2 With 6 Mg/M2 In The NCRI AML17 Trial

Burnett, A., Cavenagh, J., Russell, N., Hills, R., Kell, J., Jones, G., . . . Grp, U. K. N. C. R. I. A. M. L. S. (2016). Defining The Dose Of Gemtuzumab Ozogamicin In Combination With Induction Chemotherapy In Acute Myeloid Leukemia: A Comparison Of 3 Mg/M2 With 6 Mg/M2 In The NCRI AML17 Trial. Haematologica: the hematology journal, 101(6), 724-731. doi:10.3324/haematol.2016.141937

DOI
10.3324/haematol.2016.141937
Journal article

Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial

Hochhaus, A., Saglio, G., Hughes, T. P., Larson, R. A., Kim, D. -W., Issaragrisil, S., . . . Kantarjian, H. M. (2016). Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. LEUKEMIA, 30(5), 1044-1054. doi:10.1038/leu.2016.5

DOI
10.1038/leu.2016.5
Journal article

Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial

Lipton, J. H., Chuah, C., Guerci-Bresler, A., Rosti, G., Simpson, D., Assouline, S., . . . Investigators, E. P. I. C. (2016). Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. The Lancet Oncology, 17(5), 612-621. doi:10.1016/S1470-2045(16)00080-2

DOI
10.1016/S1470-2045(16)00080-2
Journal article

De-escalation of tyrosine kinase inhibitor treatment in chronic myeloid leukaemia patients with excellent molecular responses: Initial safety results from the DESTINY trial

Clark, R. E., Polydoros, F., Apperley, J. F., Pocock, C., Smith, G., Salim, R., . . . Copland, M. (2016). De-escalation of tyrosine kinase inhibitor treatment in chronic myeloid leukaemia patients with excellent molecular responses: Initial safety results from the DESTINY trial. In BRITISH JOURNAL OF HAEMATOLOGY Vol. 173 (pp. 12). Retrieved from https://www.webofscience.com/

Conference Paper

T cell subsets do not alter on decreasing/stopping tyrosine kinase inhibitor therapy in chronic myeloid leukaemia: Data from the DESTINY trial

Austin, G., Knight, K., Bell, J., Foroni, L., Salim, R., Christmas, S. E., . . . Clark, R. E. (2016). T cell subsets do not alter on decreasing/stopping tyrosine kinase inhibitor therapy in chronic myeloid leukaemia: Data from the DESTINY trial. In BRITISH JOURNAL OF HAEMATOLOGY Vol. 173 (pp. 119). Retrieved from https://www.webofscience.com/

Conference Paper

The Cdk2 inhibitor, Purvalanol A, induces apoptosis is myeloid cells via p38-MAPK dependent turnover of Mcl-1

Phoomvuthisarn, P., Wright, H. L., Clark, R. E., Mutirangura, A., & Edwards, S. W. (2016). The Cdk2 inhibitor, Purvalanol A, induces apoptosis is myeloid cells via p38-MAPK dependent turnover of Mcl-1. In EUROPEAN JOURNAL OF CLINICAL INVESTIGATION Vol. 46 (pp. 81). Retrieved from https://www.webofscience.com/

Conference Paper

2015

An Operational Definition of Primary Refractory Acute Myeloid Leukaemia Which Allows Early Identification of Patients for Whom Allogeneic Stem Cell Transplantation Represents the Only Curative Therapy

Ferguson, P., Hills, R. K., Grech, A., Betteridge, S., Kjeldsen, L., Dennis, M., . . . Craddock, C. (2015). An Operational Definition of Primary Refractory Acute Myeloid Leukaemia Which Allows Early Identification of Patients for Whom Allogeneic Stem Cell Transplantation Represents the Only Curative Therapy. In BLOOD Vol. 126. doi:10.1182/blood.V126.23.559.559

DOI
10.1182/blood.V126.23.559.559
Conference Paper

Assessment of Quality of Life in the NCRI Spirit 2 Study Comparing Imatinib with Dasatinib in Patients with Newly-Diagnosed Chronic Phase Chronic Myeloid Leukaemia

Labeit, A. M., Copland, M., Cork, L. M., Hedgley, C. A., Foroni, L., Osborne, W. L., . . . O'Brien, S. G. (2015). Assessment of Quality of Life in the NCRI Spirit 2 Study Comparing Imatinib with Dasatinib in Patients with Newly-Diagnosed Chronic Phase Chronic Myeloid Leukaemia. In BLOOD Vol. 126. Retrieved from https://www.webofscience.com/

Conference Paper

BGB324 Inhibits BCR-ABL TKI-Resistant Chronic Myeloid Leukemia

Ben Batalla, I., Erdmann, R., Jorgensen, H., Mitchell, R., Ernst, T., von Amsberg, G., . . . Loges, S. (2015). BGB324 Inhibits BCR-ABL TKI-Resistant Chronic Myeloid Leukemia. In BLOOD Vol. 126. Retrieved from https://www.webofscience.com/

Conference Paper

PP2A Inhibition By CIP2A or SETBP1 Leads to Elevated Levels of AKT S473 Which Can be Used As a Biomarker of Outcome in Acute Myeloid Leukaemia

Hills, R. K., Lucas, C. M., Scott, L. J., Carmell, N., Holcroft, A. K., & Clark, R. E. (2015). PP2A Inhibition By CIP2A or SETBP1 Leads to Elevated Levels of AKT S473 Which Can be Used As a Biomarker of Outcome in Acute Myeloid Leukaemia. In BLOOD Vol. 126. Retrieved from https://www.webofscience.com/

Conference Paper

Treatment and Outcome Analysis of 2,904 Pateints from the EUTOS Population Based Registry

Hoffmann, V. S., Baccarani, M., Hasford, J., Lindoerfer, D., Burgstaller, S., Sertic, D., . . . Hehlmann, R. (2015). Treatment and Outcome Analysis of 2,904 Pateints from the EUTOS Population Based Registry. In BLOOD Vol. 126. Retrieved from https://www.webofscience.com/

Conference Paper

Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial

Burnett, A. K., Russell, N. H., Hills, R. K., Bowen, D., Kell, J., Knapper, S., . . . Grimwade, D. (2015). Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. The Lancet Oncology, 16(13), 1295-1305. doi:10.1016/S1470-2045(15)00193-X

DOI
10.1016/S1470-2045(15)00193-X
Journal article

A comparative assessment of the curative potential of reduced intensity allografts in acute myeloid leukaemia

Russell, N. H., Kjeldsen, L., Craddock, C., Pagliuca, A., Yin, J. A., Clark, R. E., . . . Burnett, A. K. (2015). A comparative assessment of the curative potential of reduced intensity allografts in acute myeloid leukaemia. LEUKEMIA, 29(7), 1478-1484. doi:10.1038/leu.2014.319

DOI
10.1038/leu.2014.319
Journal article

Second generation tyrosine kinase inhibitors prevent disease progression in high-risk (high CIP2A) chronic myeloid leukaemia patients

Lucas, C., Harris, B., Holcroft, A., Scott, L., Carmell, N., McDonald, E., . . . Clark, R. (2015). Second generation tyrosine kinase inhibitors prevent disease progression in high-risk (high CIP2A) chronic myeloid leukaemia patients. Leukemia, 29(7), 1514-1523. doi:10.1038/leu.2015.71

DOI
10.1038/leu.2015.71
Journal article

Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST Trial

Mead, A. J., Milojkovic, D., Knapper, S., Garg, M., Chacko, J., Farquharson, M., . . . Harrison, C. (2015). Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST Trial. BRITISH JOURNAL OF HAEMATOLOGY, 170(1), 29-39. doi:10.1111/bjh.13379

DOI
10.1111/bjh.13379
Journal article

A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients

Burnett, A. K., Russell, N. H., Hills, R. K., Kell, J., Cavenagh, J., Kjeldsen, L., . . . Clark, R. (2015). A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients. Blood, 125(25), 3878-3885. doi:10.1182/blood-2015-01-623447

DOI
10.1182/blood-2015-01-623447
Journal article

A randomised comparison of the novel nucleoside analogue sapacitabine with low-dose cytarabine in older patients with acute myeloid leukaemia

Burnett, A. K., Russell, N., Hills, R. K., Panoskaltsis, N., Khwaja, A., Hemmaway, C., . . . Milligan, D. (2015). A randomised comparison of the novel nucleoside analogue sapacitabine with low-dose cytarabine in older patients with acute myeloid leukaemia. Leukemia, 29(6), 1312-1319. doi:10.1038/leu.2015.38

DOI
10.1038/leu.2015.38
Journal article

The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries

Hoffmann, V. S., Baccarani, M., Hasford, J., Lindoerfer, D., Burgstaller, S., Sertic, D., . . . Hehlmann, R. (2015). The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries. LEUKEMIA, 29(6), 1336-1343. doi:10.1038/leu.2015.73

DOI
10.1038/leu.2015.73
Journal article

Vosaroxin and vosaroxin plus low-dose Ara-C (LDAC) vs low-dose Ara-C alone in older patients with acute myeloid leukemia

Dennis, M., Russell, N., Hills, R. K., Hemmaway, C., Panoskaltsis, N., McMullin, M. -F., . . . Burnett, A. K. (2015). Vosaroxin and vosaroxin plus low-dose Ara-C (LDAC) vs low-dose Ara-C alone in older patients with acute myeloid leukemia. BLOOD, 125(19), 2923-2932. doi:10.1182/blood-2014-10-608117

DOI
10.1182/blood-2014-10-608117
Journal article

C-Myc inhibition decreases CIP2A and reduces BCR-ABL1 tyrosine kinase activity in chronic myeloid leukemia

Lucas, C., Harris, B., Giannoudis, A., & Clark, R. (2015). C-Myc inhibition decreases CIP2A and reduces BCR-ABL1 tyrosine kinase activity in chronic myeloid leukemia. Haematologica, 100(05), e179-e182. doi:10.3324/haematol.2014.115691

DOI
10.3324/haematol.2014.115691
Journal article

Onset and outcome of pregnancy after autologous haematopoietic SCT (AHSCT) for autoimmune diseases: a retrospective study of the EBMT autoimmune diseases working party (ADWP)

Snarski, E., Snowden, J. A., Oliveira, M. C., Simoes, B., Badoglio, M., Carlson, K., . . . Farge, D. (2015). Onset and outcome of pregnancy after autologous haematopoietic SCT (AHSCT) for autoimmune diseases: a retrospective study of the EBMT autoimmune diseases working party (ADWP). BONE MARROW TRANSPLANTATION, 50(2), 216-220. doi:10.1038/bmt.2014.248

DOI
10.1038/bmt.2014.248
Journal article

<i>PTCH1</i> expression at diagnosis predicts imatinib failure in chronic myeloid leukaemia patients in chronic phase

Alonso-Dominguez, J. M., Grinfeld, J., Alikian, M., Marin, D., Reid, A., Daghistani, M., . . . Gerrard, G. (2015). <i>PTCH1</i> expression at diagnosis predicts imatinib failure in chronic myeloid leukaemia patients in chronic phase. AMERICAN JOURNAL OF HEMATOLOGY, 90(1), 20-26. doi:10.1002/ajh.23857

DOI
10.1002/ajh.23857
Journal article

APL of all risk groups is highly curable with a chemo-free combination of attenuated arsenic trioxide and ATRA

Burnett, A. K., Russell, N. H., Hills, R. K., Khwaja, A., Cavenagh, J., Friis, L., . . . Grimwade, D. (2015). APL of all risk groups is highly curable with a chemo-free combination of attenuated arsenic trioxide and ATRA. In BRITISH JOURNAL OF HAEMATOLOGY Vol. 169 (pp. 16). Retrieved from https://www.webofscience.com/

Conference Paper

EFFICACY AND SAFETY OF NILOTINIB VS IMATINIB IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE: 6-YEAR FOLLOW-UP OF ENESTND

Hughes, T. P., Larson, R. A., Kim, D. W., Issaragrisil, S., le Coutre, P. D., Lobo, C., . . . Kantarjian, H. M. (2015). EFFICACY AND SAFETY OF NILOTINIB VS IMATINIB IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE: 6-YEAR FOLLOW-UP OF ENESTND. In HAEMATOLOGICA Vol. 100 (pp. 61). Retrieved from https://www.webofscience.com/

Conference Paper

Evidence that the pregnane X and retinoid receptors PXR, RAR and RXR may regulate transcription of the transporter <i>hOCT1</i> in chronic myeloid leukaemia cells

Austin, G., Holcroft, A., Rinne, N., Wang, L., & Clark, R. E. (2015). Evidence that the pregnane X and retinoid receptors PXR, RAR and RXR may regulate transcription of the transporter <i>hOCT1</i> in chronic myeloid leukaemia cells. EUROPEAN JOURNAL OF HAEMATOLOGY, 94(1), 74-78. doi:10.1111/ejh.12409

DOI
10.1111/ejh.12409
Journal article

Systematic review to examine the clinical effectiveness and tolerability of systemic anti-cancer therapy for older people with chronic myeloid leukaemia

Bates, V., Pilkington, G. M., Dickson, R. C., Boland, A., Dundar, Y., & Clark, R. (n.d.). Systematic review to examine the clinical effectiveness and tolerability of systemic anti-cancer therapy for older people with chronic myeloid leukaemia.

Report

2014

A Comparison of Single Dose Gemtuzumab Ozogamicin 3mg/m<SUP>2</SUP> and 6mg/m<SUP>2</SUP> Combined with Induction Chemotherapy in Younger Patients with AML: Data from the UK NCRI AML17 Trial

Burnett, A. K., Russell, N., Hills, R. K., Cavenagh, J., Kell, J., Jones, G., . . . Clark, R. E. (2014). A Comparison of Single Dose Gemtuzumab Ozogamicin 3mg/m<SUP>2</SUP> and 6mg/m<SUP>2</SUP> Combined with Induction Chemotherapy in Younger Patients with AML: Data from the UK NCRI AML17 Trial. In BLOOD Vol. 124. Retrieved from https://www.webofscience.com/

Conference Paper

A Randomised Assessment of Vosaroxin Monotherapy and Vosaroxin Combined with Low Dose Ara-C Versus Low Dose Ara-C in Older Patients with Acute Myeloid Leukaemia

Dennis, M., Russell, N. H., Panoskaltsis, N., Hemmaway, C. J., Milligan, D., Clark, R. E., . . . Burnett, A. K. (2014). A Randomised Assessment of Vosaroxin Monotherapy and Vosaroxin Combined with Low Dose Ara-C Versus Low Dose Ara-C in Older Patients with Acute Myeloid Leukaemia. In BLOOD Vol. 124. Retrieved from https://www.webofscience.com/

Conference Paper

A Randomised Comparison of Daunorubicin 90mg/m<SUP>2</SUP> Vs 60mg/m<SUP>2</SUP> in AML Induction: Results from the UK NCRI AML17 Trial in 1206 Patients

Burnett, A. K., Russell, N., Hills, R. K., Kell, J., Cavenagh, J., Kjeldsen, L., . . . Clark, R. E. (2014). A Randomised Comparison of Daunorubicin 90mg/m<SUP>2</SUP> Vs 60mg/m<SUP>2</SUP> in AML Induction: Results from the UK NCRI AML17 Trial in 1206 Patients. In BLOOD Vol. 124. Retrieved from https://www.webofscience.com/

Conference Paper

A Randomised Comparison of the Sequential Addition of the FLT3 Inhibitor Lestaurtinib (CEP701) to Standard First Line Chemotherapy for FLT3-Mutated Acute Myeloid Leukemia: The UK Experience

Knapper, S., Hills, R. K., Cavenagh, J. D., Kjeldsen, L., Hunter, A. E., Clark, R. E., . . . Burnett, A. K. (2014). A Randomised Comparison of the Sequential Addition of the FLT3 Inhibitor Lestaurtinib (CEP701) to Standard First Line Chemotherapy for FLT3-Mutated Acute Myeloid Leukemia: The UK Experience. In BLOOD Vol. 124. Retrieved from https://www.webofscience.com/

Conference Paper

BGB324 Represents an Axl and BCR-ABL1 Inhibitor with Activity in the T315I Mutant

Erdmann, R., Jorgensen, H., Ben-Batalla, I., Kruse, N., Micklem, D., von Amsberg, G., . . . Loges, S. (2014). BGB324 Represents an Axl and BCR-ABL1 Inhibitor with Activity in the T315I Mutant. In BLOOD Vol. 124. Retrieved from https://www.webofscience.com/

Conference Paper

Baseline Characteristics of CML Patients Accross Europe - Comparing Real-World Patients with Patient Collectives Included in Clinical Trials

Baccarani, M., Hoffmann, V. S., Rosti, G., Castagnetti, F., Saussele, S., Guilhot, J., . . . Lindoerfer, D. (2014). Baseline Characteristics of CML Patients Accross Europe - Comparing Real-World Patients with Patient Collectives Included in Clinical Trials. BLOOD, 124(21). Retrieved from https://www.webofscience.com/

Journal article

CMV~IMPACT: Results of a Randomized Controlled Trial of Immuno-Prophylactic Adoptive Cellular Therapy following Sibling Donor Allogeneic HSCT

Peggs, K. S., Tholouli, E., Chakraverty, R., Nikolousis, E., Bloor, A., Devereux, S., . . . Moss, P. (2014). CMV~IMPACT: Results of a Randomized Controlled Trial of Immuno-Prophylactic Adoptive Cellular Therapy following Sibling Donor Allogeneic HSCT. Blood, 124(21), 1109. doi:10.1182/blood.v124.21.1109.1109

DOI
10.1182/blood.v124.21.1109.1109
Journal article

Efficacy and Safety of Nilotinib (NIL) vs Imatinib (IM) in Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Long-Term Follow-Up (f/u) of ENESTnd

Larson, R. A., Kim, D. -W., Issaragrilsil, S., le Coutre, P., Dorlhiac Llacer, P. E., Etienne, G., . . . Hughes, T. P. (2014). Efficacy and Safety of Nilotinib (NIL) vs Imatinib (IM) in Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Long-Term Follow-Up (f/u) of ENESTnd. In BLOOD Vol. 124. doi:10.1182/blood.V124.21.1804.1804

DOI
10.1182/blood.V124.21.1804.1804
Conference Paper

Efficacy and Safety of Nilotinib (NIL) vs Imatinib (IM) in Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Long-Term Follow-Up (f/u) of ENESTnd

Larson, R. A., Kim, D. -W., Issaragrilsil, S., le Coutre, P., Dorlhiac Llacer, P. E., Etienne, G., . . . Hughes, T. P. (2014). Efficacy and Safety of Nilotinib (NIL) vs Imatinib (IM) in Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Long-Term Follow-Up (f/u) of ENESTnd. Blood, 124(21), 4541. doi:10.1182/blood.v124.21.4541.4541

DOI
10.1182/blood.v124.21.4541.4541
Journal article

Epic: A Phase 3 Trial of Ponatinib Compared with Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CP-CML)

Lipton, J. H., Chuah, C., Guerci-Bresler, A., Rosti, G., Simpson, D., Assouline, S., . . . Deininger, M. W. (2014). Epic: A Phase 3 Trial of Ponatinib Compared with Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CP-CML). In BLOOD Vol. 124. Retrieved from https://www.webofscience.com/

Conference Paper

Incidence of CML in Europe -- a Comparison of 19 European Countries with US SEER Data

Hoffmann, V. S., Lindoerfer, D., Thaler, J., Boris, L., Melanthiou, F., Mayer, J., . . . Baccarani, M. (2014). Incidence of CML in Europe -- a Comparison of 19 European Countries with US SEER Data. In BLOOD Vol. 124. Retrieved from https://www.webofscience.com/

Conference Paper

Leukemia Stem Cell Potential of Different Progenitor Subpopulations in Myeloid Blast Phase CML

Kinstrie, R., Karamitros, D., Goardon, N., Morrison, H., Clark, R. E., Vyas, P., & Copland, M. (2014). Leukemia Stem Cell Potential of Different Progenitor Subpopulations in Myeloid Blast Phase CML. In BLOOD Vol. 124. Retrieved from https://www.webofscience.com/

Conference Paper

Spirit 2: An NCRI Randomised Study Comparing Dasatinib with Imatinib in Patients with Newly Diagnosed CML

O'Brien, S. G., Hedgley, C., Adams, S., Foroni, L., Apperley, J. F., Holyoake, T. L., . . . Clark, R. E. (2014). Spirit 2: An NCRI Randomised Study Comparing Dasatinib with Imatinib in Patients with Newly Diagnosed CML. In BLOOD Vol. 124. Retrieved from https://www.webofscience.com/

Conference Paper

Dual Glutathione-<i>S</i>-Transferase-θ1 and -μ1 Gene Deletions Determine Imatinib Failure in Chronic Myeloid Leukemia

Davies, A., Giannoudis, A., Zhang, J. E., Austin, G., Wang, L., Holyoake, T. L., . . . Clark, R. E. (2014). Dual Glutathione-<i>S</i>-Transferase-θ1 and -μ1 Gene Deletions Determine Imatinib Failure in Chronic Myeloid Leukemia. CLINICAL PHARMACOLOGY & THERAPEUTICS, 96(6), 694-703. doi:10.1038/clpt.2014.176

DOI
10.1038/clpt.2014.176
Journal article

Low leukotriene B4 receptor 1 leads to ALOX5 downregulation at diagnosis of chronic myeloid leukemia

Lucas, C. M., Harris, R. J., Giannoudis, A., McDonald, E., & Clark, R. E. (2014). Low leukotriene B4 receptor 1 leads to ALOX5 downregulation at diagnosis of chronic myeloid leukemia. HAEMATOLOGICA, 99(11), 1710-1715. doi:10.3324/haematol.2013.101972

DOI
10.3324/haematol.2013.101972
Journal article

Plerixafor is superior to conventional chemotherapy for first-line stem cell mobilisation, and is effective even in heavily pretreated patients

Clark, R. E., Bell, J., Clark, J. O., Braithwaite, B., Vithanarachchi, U., McGinnity, N., . . . Salim, R. (2014). Plerixafor is superior to conventional chemotherapy for first-line stem cell mobilisation, and is effective even in heavily pretreated patients. BLOOD CANCER JOURNAL, 4. doi:10.1038/bcj.2014.79

DOI
10.1038/bcj.2014.79
Journal article

ENESTnd 5-year (y) update: Long-term outcomes of patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with frontline nilotinib (NIL) versus imatinib (IM).

Larson, R. A., Kim, D. -W., Jootar, S., Pasquini, R., Clark, R. E., Lobo, C., . . . Hughes, T. P. (2014). ENESTnd 5-year (y) update: Long-term outcomes of patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with frontline nilotinib (NIL) versus imatinib (IM).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 32 (pp. 7073). doi:10.1200/jco.2014.32.15_suppl.7073

DOI
10.1200/jco.2014.32.15_suppl.7073
Conference Paper

Tuesday 29th April 2014 Free Communication John Goldman Memorial Symposium

O'Brien, S. G., Clark, R. E., Hedgley, C., Apperley, J., Foroni, L., Pocock, C., . . . Goldman, J. M. (2014). Tuesday 29th April 2014 Free Communication John Goldman Memorial Symposium. In BRITISH JOURNAL OF HAEMATOLOGY Vol. 165 (pp. 1). doi:10.1111/bjh.12803

DOI
10.1111/bjh.12803
Conference Paper

A NATIONAL EXPERIENCE OF THE USE OF PONATINIB IN PATIENTS MULTIPLE TYROSINE KINASE INHIBITORS CONFIRMS EFFICACY IN A HEAVILY PRE-TREATED COHORT OF PATIENTS WITH PH plus LEUKAEMIAS

Milojkovic, D., Bakir, A., Whitehead, L., Byrne, J., Clark, R. E., Copland, M., . . . Apperley, J. (2014). A NATIONAL EXPERIENCE OF THE USE OF PONATINIB IN PATIENTS MULTIPLE TYROSINE KINASE INHIBITORS CONFIRMS EFFICACY IN A HEAVILY PRE-TREATED COHORT OF PATIENTS WITH PH plus LEUKAEMIAS. In HAEMATOLOGICA Vol. 99 (pp. 335). Retrieved from https://www.webofscience.com/

Conference Paper

Alox5 is down-regulated at diagnosis of chronic myeloid leukaemia

Lucas, C. M., Harris, R. J., Giannoudis, A., McDonald, E., & Clark, R. E. (2014). Alox5 is down-regulated at diagnosis of chronic myeloid leukaemia. Haematologica, epub, September 5th 2014.

Journal article

CMV∼IMPACT: Results of a Randomized Controlled Trial of Immuno-Prophylactic Adoptive Cellular Therapy following Sibling Donor Allogeneic HSCT

Peggs, K. S., Tholouli, E., Chakraverty, R., Nikolousis, E., Bloor, A., Devereux, S., . . . Moss, P. (2014). CMV∼IMPACT: Results of a Randomized Controlled Trial of Immuno-Prophylactic Adoptive Cellular Therapy following Sibling Donor Allogeneic HSCT. In BLOOD Vol. 124. Retrieved from https://www.webofscience.com/

Conference Paper

Fertility recovery and pregnancy after autologous hematopoietic stem cell transplantation for autoimmune diseases: a retrospective study of the EBMT Autoimmune Diseases Working Party

Snarski, E., Snowden, J. A., Oliveira, M. C., Simoes, B., Badoglio, M., Carlson, K., . . . Farge, D. (2014). Fertility recovery and pregnancy after autologous hematopoietic stem cell transplantation for autoimmune diseases: a retrospective study of the EBMT Autoimmune Diseases Working Party. Blood & Marrow Transplantation, in pre, accepted 18 Sept 2014.

Journal article

Ikaros transcripts Ik6/10 and levels of full-length transcript are critical for chronic myeloid leukaemia blast crisis transformation

Wang, L. H., Howarth, A., & Clark, R. E. (2014). Ikaros transcripts Ik6/10 and levels of full-length transcript are critical for chronic myeloid leukaemia blast crisis transformation. Leukemia, 28, 1745-1747. doi:10.1038/leu.2014.99

DOI
10.1038/leu.2014.99
Journal article

PLERIXAFOR IS COST-EFFECTIVE FOR FIRST LINE STEM CELL MOBILISATION: INDIVIDUAL PATIENT COSTING ANALYSIS OF THE LIVERPOOL PHANTASTIC TRIAL

Haycox, A., Richards, S., & Clark, R. E. (2014). PLERIXAFOR IS COST-EFFECTIVE FOR FIRST LINE STEM CELL MOBILISATION: INDIVIDUAL PATIENT COSTING ANALYSIS OF THE LIVERPOOL PHANTASTIC TRIAL. In HAEMATOLOGICA Vol. 99 (pp. 490-491). Retrieved from https://www.webofscience.com/

Conference Paper

THE EUTOS POPULATION BASED REGISTRY - INCIDENCES OF CML ACROSS EUROPE

Hoffmann, V., Lindoerfer, D., Thaler, J., Labar, B., Melanthiou, F., Mayer, J., . . . Baccarani, M. (2014). THE EUTOS POPULATION BASED REGISTRY - INCIDENCES OF CML ACROSS EUROPE. In HAEMATOLOGICA Vol. 99 (pp. 72). Retrieved from https://www.webofscience.com/

Conference Paper

THE EUTOS POPULATION-BASED REGISTRY: EVALUATION OF BASELINE CHARACTERISTICS AND FIRST TREATMENT CHOICES OF 2983 NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA (CML) PATIENTS FROM 20 EUROPEAN COUNTRIES

Lindoerfer, D., Hoffmann, V. S., Rosti, G., Castagnetti, F., Saussele, S., Guilhot, J., . . . Baccarani, M. (2014). THE EUTOS POPULATION-BASED REGISTRY: EVALUATION OF BASELINE CHARACTERISTICS AND FIRST TREATMENT CHOICES OF 2983 NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA (CML) PATIENTS FROM 20 EUROPEAN COUNTRIES. In HAEMATOLOGICA Vol. 99 (pp. 238-239). Retrieved from https://www.webofscience.com/

Conference Paper

TRANSCRIPT LEVELS OF THE HEDGEHOG PATHWAY MEMBERS PTCH1 AND SMO ARE PREDICTIVE OF IMATINIB FAILURE IN PRE-TREATMENT CHRONIC MYELOID LEUKAEMIA

Gerrard, G., Hagkarim, N. C., Szydlo, R., Alikian, M., Alonso-Dominguez, J. M., Grinfeld, J., . . . Foroni, L. (2014). TRANSCRIPT LEVELS OF THE HEDGEHOG PATHWAY MEMBERS PTCH1 AND SMO ARE PREDICTIVE OF IMATINIB FAILURE IN PRE-TREATMENT CHRONIC MYELOID LEUKAEMIA. In HAEMATOLOGICA Vol. 99 (pp. 510). Retrieved from https://www.webofscience.com/

Conference Paper

The clinical significance of ABCC3 as an imatinib transporter in chronic myeloid leukaemia

Giannoudis, A., Davies, A., Harris, B., Lucas, C., Pirmohamed, M., & Clark, R. (2014). The clinical significance of ABCC3 as an imatinib transporter in chronic myeloid leukaemia. Leukemia, 28(6), 1360-1363. doi:10.1038/leu.2014.38

DOI
10.1038/leu.2014.38
Journal article

2013

A common novel splice variant of <i>SLC22A1</i> (<i>OCT1</i>) is associated with impaired responses to imatinib in patients with chronic myeloid leukaemia

Grinfeld, J., Gerrard, G., Alikian, M., Alonso-Dominguez, J., Ale, S., Valganon, M., . . . Foroni, L. (2013). A common novel splice variant of <i>SLC22A1</i> (<i>OCT1</i>) is associated with impaired responses to imatinib in patients with chronic myeloid leukaemia. BRITISH JOURNAL OF HAEMATOLOGY, 163(5), 631-639. doi:10.1111/bjh.12591

DOI
10.1111/bjh.12591
Journal article

Safety and efficacy of pulsed imatinib with or without G-CSF versus continuous imatinib in chronic phase chronic myeloid leukaemia patients at 5 years follow-up.

Gallipoli, P., Stobo, J., Heaney, N., Nicolini, F. E., Clark, R., Wilson, G., . . . Holyoake, T. L. (2013). Safety and efficacy of pulsed imatinib with or without G-CSF versus continuous imatinib in chronic phase chronic myeloid leukaemia patients at 5 years follow-up.. British journal of haematology, 163(5), 674-676. doi:10.1111/bjh.12532

DOI
10.1111/bjh.12532
Journal article

Dose Interruption/Reduction Of Tyrosine Kinase Inhibitors In The First 3 Months Of Treatment of CML Is Associated With Inferior Early Molecular Responses and Predicts For An Increased Likelihood Of Discontinuation Of The 1st Line Agent

Apperley, J. F., Szydlo, R. M., Gerrard, G., McCue, J. R., Wardle, J., Clark, R. E., . . . Foroni, L. (2013). Dose Interruption/Reduction Of Tyrosine Kinase Inhibitors In The First 3 Months Of Treatment of CML Is Associated With Inferior Early Molecular Responses and Predicts For An Increased Likelihood Of Discontinuation Of The 1st Line Agent. Blood, 122(21), 93. doi:10.1182/blood.v122.21.93.93

DOI
10.1182/blood.v122.21.93.93
Journal article

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

Baccarani, M., Deininger, M. W., Rosti, G., Hochhaus, A., Soverini, S., Apperley, J. F., . . . Hehlmann, R. (2013). European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.. Blood, 122(6), 872-884. doi:10.1182/blood-2013-05-501569

DOI
10.1182/blood-2013-05-501569
Journal article

A population study showing that the advent of second generation tyrosine kinase inhibitors has improved progression-free survival in chronic myeloid leukaemia.

Francis, S., Lucas, C., Lane, S., Wang, L., Watmough, S., Knight, K., . . . Clark, R. E. (2013). A population study showing that the advent of second generation tyrosine kinase inhibitors has improved progression-free survival in chronic myeloid leukaemia.. Leukemia research, 37(7), 752-758. doi:10.1016/j.leukres.2013.04.003

DOI
10.1016/j.leukres.2013.04.003
Journal article

The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts.

Experts in Chronic Myeloid Leukemia. (2013). The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts.. Blood, 121(22), 4439-4442. doi:10.1182/blood-2013-03-490003

DOI
10.1182/blood-2013-03-490003
Journal article

Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies

Neelakantan, P., Gerrard, G., Lucas, C., Milojkovic, D., May, P., Wang, L., . . . Marin, D. (2013). Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies. BLOOD, 121(14), 2739-2742. doi:10.1182/blood-2012-11-466037

DOI
10.1182/blood-2012-11-466037
Journal article

The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia

Giannoudis, A., Wang, L., Jorgensen, A. L., Xinarianos, G., Davies, A., Pushpakom, S., . . . Clark, R. E. (2013). The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia. BLOOD, 121(4), 628-637. doi:10.1182/blood-2012-01-405035

DOI
10.1182/blood-2012-01-405035
Journal article

Can the combined assessment of BCR-ABL1 transcript levels at 3 and 6 months improve the prognostic value of the 3 month measurement for CML patients who start treatment with tyrosine kinase inhibitors? Implications for early intervention strategies

Neelakantan, P., Gerrard, G., Lucas, C. M., Hedgley, C., Milojkovic, D., May, P., . . . Marin, D. (2013). Can the combined assessment of BCR-ABL1 transcript levels at 3 and 6 months improve the prognostic value of the 3 month measurement for CML patients who start treatment with tyrosine kinase inhibitors? Implications for early intervention strategies. Blood, 121, 2739-2742.

Journal article

Pulsed imatinib with or without G-CSF is a safe treatment approach and potentially improves molecular responses in CML patients in complete cytogenetic response compared to continuous imatinib: results from 5 years follow-up of a pilot study (GIMI)

Gallipoli, P., Stobo, J., Heaney, N., Kaeda, J., Nicolini, F. E., Clark, R. E., . . . Holyoake, T. L. (2013). Pulsed imatinib with or without G-CSF is a safe treatment approach and potentially improves molecular responses in CML patients in complete cytogenetic response compared to continuous imatinib: results from 5 years follow-up of a pilot study (GIMI). British Journal of Haematology, 163, 674-676.

Journal article

Response to the letter to the Editor. Tzvetkov et al, "The hOCT1 SNPs Met420del and Met408Val alter imatinib uptake: Does the apparently predictive haplotype Met408-Del420 really exist"?

Giannoudis, A., Pirmohamed, M., & Clark, R. E. (2013). Response to the letter to the Editor. Tzvetkov et al, "The hOCT1 SNPs Met420del and Met408Val alter imatinib uptake: Does the apparently predictive haplotype Met408-Del420 really exist"?. Blood e-letters. Retrieved from http://bloodjournal.hematologylibrary.org/

Journal article

The hOCT1 single nucleotide polymorphisms M420del and M408V alter imatinib uptake and modify clinical outcome in imatinib treated chronic myeloid leukaemia

Giannoudis, A., Wang, L., Jorgensen, A. L., Xinarianos, G., Davies, A., Pushpakom, S., . . . Clark, R. E. (2013). The hOCT1 single nucleotide polymorphisms M420del and M408V alter imatinib uptake and modify clinical outcome in imatinib treated chronic myeloid leukaemia. Blood, 121, 628-637.

Journal article

2012

A Novel Splice Site Variant of hOCT-1 and Response to Imatinib.

Grinfeld, J., Alonso-Dominguez, J. M., Alikian, M., Valgañón, M., Nteliopoulos, G., White, D. L., . . . Gerrard, G. (2012). A Novel Splice Site Variant of hOCT-1 and Response to Imatinib.. Blood, 120(21), 2555. doi:10.1182/blood.v120.21.2555.2555

DOI
10.1182/blood.v120.21.2555.2555
Journal article

PTCH1 Expression At Diagnosis Reliably Predicts Treatment Failure in Imatinib-Treated Chronic Myeloid Leukaemia Patients

Alonso-Dominguez, J. M., Grinfeld, J., Alikian, M., Marin, D., Reid, A., Daghistani, M., . . . Gerrard, G. (2012). PTCH1 Expression At Diagnosis Reliably Predicts Treatment Failure in Imatinib-Treated Chronic Myeloid Leukaemia Patients. In BLOOD Vol. 120. doi:10.1182/blood.V120.21.875.875

DOI
10.1182/blood.V120.21.875.875
Conference Paper

Erratum: Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up

Larson, R. A., Hochhaus, A., Hughes, T. P., Clark, R. E., Etienne, G., Kim, D. -W., . . . Kantarjian, H. M. (2012). Erratum: Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia, 26(10), 2302. doi:10.1038/leu.2012.175

DOI
10.1038/leu.2012.175
Journal article

Serine 162, an Essential Residue for the Mitochondrial Localization, Stability and Anti-Apoptotic Function of Mcl-1

Thomas, L. W., Lam, C., Clark, R. E., White, M. R. H., Spiller, D. G., Moots, R. J., & Edwards, S. W. (2012). Serine 162, an Essential Residue for the Mitochondrial Localization, Stability and Anti-Apoptotic Function of Mcl-1. PLOS ONE, 7(9). doi:10.1371/journal.pone.0045088

DOI
10.1371/journal.pone.0045088
Journal article

Dasatinib may overcome the negative prognostic impact of KIR2DS1 in newly diagnosed patients with chronic myeloid leukemia.

Ali, S., Sergeant, R., O'Brien, S. G., Foroni, L., Hedgley, C., Gerrard, G., . . . Rezvani, K. (2012). Dasatinib may overcome the negative prognostic impact of KIR2DS1 in newly diagnosed patients with chronic myeloid leukemia.. Blood, 120(3), 697-698. doi:10.1182/blood-2012-04-421016

DOI
10.1182/blood-2012-04-421016
Journal article

Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib

Marin, D., Hedgley, C., Clark, R. E., Apperley, J., Foroni, L., Milojkovic, D., . . . O'Brien, S. (2012). Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib. BLOOD, 120(2), 291-294. doi:10.1182/blood-2012-01-407486

DOI
10.1182/blood-2012-01-407486
Journal article

Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet.

Guilhot, J., Baccarani, M., Clark, R. E., Cervantes, F., Guilhot, F., Hochhaus, A., . . . Hehlmann, R. (2012). Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet.. Blood, 119(25), 5963-5971. doi:10.1182/blood-2011-10-383711

DOI
10.1182/blood-2011-10-383711
Journal article

Haematopoietic stem cell transplantation (HSCT) in severe autoimmune diseases: analysis of UK outcomes from the British Society of Blood and Marrow Transplantation (BSBMT) data registry 1997-2009.

Snowden, J. A., Pearce, R. M., Lee, J., Kirkland, K., Gilleece, M., Veys, P., . . . BSBMT Clinical Trials Committee. (2012). Haematopoietic stem cell transplantation (HSCT) in severe autoimmune diseases: analysis of UK outcomes from the British Society of Blood and Marrow Transplantation (BSBMT) data registry 1997-2009.. British journal of haematology, 157(6), 742-746. doi:10.1111/j.1365-2141.2012.09122.x

DOI
10.1111/j.1365-2141.2012.09122.x
Journal article

Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase.

Larson, R. A., Yin, O. Q. P., Hochhaus, A., Saglio, G., Clark, R. E., Nakamae, H., . . . le Coutre, P. D. (2012). Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase.. European journal of clinical pharmacology, 68(5), 723-733. doi:10.1007/s00228-011-1200-7

DOI
10.1007/s00228-011-1200-7
Journal article

Release of intracellular calcium primes chronic myeloid leukaemia cells for tyrosine kinase inhibitor-induced apoptosis

Forchap, S. L., Pirmohamed, M., & Clark, R. E. (2012). Release of intracellular calcium primes chronic myeloid leukaemia cells for tyrosine kinase inhibitor-induced apoptosis. LEUKEMIA, 26(3), 490-498. doi:10.1038/leu.2011.231

DOI
10.1038/leu.2011.231
Journal article

Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.

Marin, D., Ibrahim, A. R., Lucas, C., Gerrard, G., Wang, L., Szydlo, R. M., . . . Foroni, L. (2012). Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30(3), 232-238. doi:10.1200/jco.2011.38.6565

DOI
10.1200/jco.2011.38.6565
Journal article

Haemopoietic stem cell transplantation in severe autoimmune diseases: Analysis of UK outcomes from the BSBMT database 1997-2009

Snowden, J. A., Pearce, R. M., Lee, J., Kirkland, K., Gilleece, M., Veys, P., . . . Cook, G. (2012). Haemopoietic stem cell transplantation in severe autoimmune diseases: Analysis of UK outcomes from the BSBMT database 1997-2009. British Journal of Haematology, 157, 742-746.

Journal article

KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib

Marin, D., Gabriel, I. H., Ahmad, S., Foroni, L., de Lavallade, H., Clark, R., . . . Rezvani, K. (2012). KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib. LEUKEMIA, 26(2), 296-302. doi:10.1038/leu.2011.180

DOI
10.1038/leu.2011.180
Journal article

Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up.

Larson, R. A., Hochhaus, A., Hughes, T. P., Clark, R. E., Etienne, G., Kim, D. -W., . . . Kantarjian, H. M. (2012). Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up.. Leukemia, 26(10), 2197-2203. doi:10.1038/leu.2012.134

DOI
10.1038/leu.2012.134
Journal article

Peroxisome proliferator-activated receptor activation increases imatinib uptake and killing of chronic myeloid leukemia cells

Wang, L., Giannoudis, A., Austin, G., & Clark, R. E. (2012). Peroxisome proliferator-activated receptor activation increases imatinib uptake and killing of chronic myeloid leukemia cells. EXPERIMENTAL HEMATOLOGY, 40(10), 811-819. doi:10.1016/j.exphem.2012.05.013

DOI
10.1016/j.exphem.2012.05.013
Journal article

Peroxisome proliferator-activated receptors (PPAR) upregulate the imatinib transporter hOCT1 in chronic myeloid leukaemia

Wang, L., Giannoudis, A., Austin, G., & Clark, R. E. (2012). Peroxisome proliferator-activated receptors (PPAR) upregulate the imatinib transporter hOCT1 in chronic myeloid leukaemia. Experimental Hematology, 40, 811-819.

Journal article

The predictive value of early molecular response in patients with chronic myeloid leukaemia in chronic phase treated with dasatinib as first line therapy.

Marin, D., Hedgley, C., Clark, R. E., Apperley, J. F., Foroni, L., Milojkovic, D., . . . O'Brien, S. (2012). The predictive value of early molecular response in patients with chronic myeloid leukaemia in chronic phase treated with dasatinib as first line therapy.. Blood, 120, 291-294.

Journal article

2011

Second-generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failed.

Ibrahim, A. R., Clark, R. E., Holyoake, T. L., Byrne, J., Shepherd, P., Apperley, J. F., . . . Marin, D. (2011). Second-generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failed.. Haematologica, 96(12), 1779-1782. doi:10.3324/haematol.2011.049759

DOI
10.3324/haematol.2011.049759
Journal article

Assessment of BCR-ABL1 Transcript Levels At 3 Months Is the Only Requirement for Predicting Outcome for Patients with Chronic Myeloid Leukemia Treated with Imatinib

Milojkovic, D., Ibrahim, A. R., Foroni, L., Lucas, C., Gerrard, G., Wang, L., . . . Marin, D. (2011). Assessment of BCR-ABL1 Transcript Levels At 3 Months Is the Only Requirement for Predicting Outcome for Patients with Chronic Myeloid Leukemia Treated with Imatinib. Blood, 118(21), 1680. doi:10.1182/blood.v118.21.1680.1680

DOI
10.1182/blood.v118.21.1680.1680
Journal article

The Predictive Value of Early Molecular Response in Chronic Phase CML Patients Treated with Dasatinib First Line Therapy

Marin, D., Hedgley, C., Clark, R. E., Apperley, J. F., Foroni, L., Milojkovic, D., . . . O'Brien, S. (2011). The Predictive Value of Early Molecular Response in Chronic Phase CML Patients Treated with Dasatinib First Line Therapy. Blood, 118(21), 785. doi:10.1182/blood.v118.21.785.785

DOI
10.1182/blood.v118.21.785.785
Journal article

Rapid diagnosis of chronic myeloid leukemia by flow cytometric detection of BCR-ABL1 protein

Lucas, C. M., Fagan, J. L., Carter, A., Swale, B., Evans, C., Clark, R. E., & Harris, R. J. (2011). Rapid diagnosis of chronic myeloid leukemia by flow cytometric detection of BCR-ABL1 protein. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 96(7), 1077-1078. doi:10.3324/haematol.2011.043166

DOI
10.3324/haematol.2011.043166
Journal article

Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression

Lucas, C. M., Harris, R. J., Giannoudis, A., Copland, M., Slupsky, J. R., & Clark, R. E. (2011). Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression. BLOOD, 117(24), 6660-6668. doi:10.1182/blood-2010-08-304477

DOI
10.1182/blood-2010-08-304477
Journal article

Loss or inhibition of stromal-derived PlGF prolongs survival of mice with imatinib-resistant Bcr-Abl1(+) leukemia.

Schmidt, T., Kharabi Masouleh, B., Loges, S., Cauwenberghs, S., Fraisl, P., Maes, C., . . . Carmeliet, P. (2011). Loss or inhibition of stromal-derived PlGF prolongs survival of mice with imatinib-resistant Bcr-Abl1(+) leukemia.. Cancer cell, 19(6), 740-753. doi:10.1016/j.ccr.2011.05.007

DOI
10.1016/j.ccr.2011.05.007
Journal article

BCR-ABL peptide vaccination in healthy subjects: immunological responses are equivalent to those in chronic myeloid leukaemia patients.

Rojas, J. M., Knight, K., Watmough, S., Bell, J., Wang, L., Callaghan, T., & Clark, R. E. (2011). BCR-ABL peptide vaccination in healthy subjects: immunological responses are equivalent to those in chronic myeloid leukaemia patients.. Leukemia research, 35(3), 369-372. doi:10.1016/j.leukres.2010.05.028

DOI
10.1016/j.leukres.2010.05.028
Journal article

A prospective evaluation of cardiac function in patients with chronic myeloid leukaemia treated with imatinib.

Estabragh, Z. R., Knight, K., Watmough, S. J., Lane, S., Vinjamuri, S., Hart, G., & Clark, R. E. (2011). A prospective evaluation of cardiac function in patients with chronic myeloid leukaemia treated with imatinib.. Leukemia research, 35(1), 49-51. doi:10.1016/j.leukres.2010.08.020

DOI
10.1016/j.leukres.2010.08.020
Journal article

2010

EVI-1 oncogene expression predicts survival in chronic-phase CML patients resistant to imatinib treated with second-generation tyrosine kinase inhibitors.

Daghistani, M., Marin, D., Khorashad, J. S., Wang, L., May, P. C., Paliompeis, C., . . . Reid, A. G. (2010). EVI-1 oncogene expression predicts survival in chronic-phase CML patients resistant to imatinib treated with second-generation tyrosine kinase inhibitors.. Blood, 116(26), 6014-6017. doi:10.1182/blood-2010-01-264234

DOI
10.1182/blood-2010-01-264234
Journal article

Naturally occurring CD4+ CD25+ FOXP3+ T-regulatory cells are increased in chronic myeloid leukemia patients not in complete cytogenetic remission and can be immunosuppressive.

Rojas, J. M., Wang, L., Owen, S., Knight, K., Watmough, S. J., & Clark, R. E. (2010). Naturally occurring CD4+ CD25+ FOXP3+ T-regulatory cells are increased in chronic myeloid leukemia patients not in complete cytogenetic remission and can be immunosuppressive.. Experimental hematology, 38(12), 1209-1218. doi:10.1016/j.exphem.2010.09.004

DOI
10.1016/j.exphem.2010.09.004
Journal article

Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: the ENESTnd study.

Giles, F. J., Rosti, G., Beris, P., Clark, R. E., le Coutre, P., Mahon, F. -X., . . . Saglio, G. (2010). Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: the ENESTnd study.. Expert review of hematology, 3(6), 665-673. doi:10.1586/ehm.10.61

DOI
10.1586/ehm.10.61
Journal article

Analysis of BCR-ABL1 Tyrosine Kinase Domain Mutations In Primitive Chronic Myeloid Leukemia Cells Identifies a Unique Mutator Phenotype.

Jiang, X., Grant, H., Stebbing, J., Foroni, L., Craddock, C., Griffiths, M., . . . Woolfson, A. (2010). Analysis of BCR-ABL1 Tyrosine Kinase Domain Mutations In Primitive Chronic Myeloid Leukemia Cells Identifies a Unique Mutator Phenotype.. Blood, 116(21), 3397. doi:10.1182/blood.v116.21.3397.3397

DOI
10.1182/blood.v116.21.3397.3397
Journal article

KIR2DS1 Genotype Predicts for Cytogenetic Response, Progression-Free Survival and Overall Survival In Patients with Chronic Phase CML on Imatinib

Gabriel, I. H., Marin, D., Ahmad, S., Foroni, L., de Lavallade, H., Clark, R. E., . . . Rezvani, K. (2010). KIR2DS1 Genotype Predicts for Cytogenetic Response, Progression-Free Survival and Overall Survival In Patients with Chronic Phase CML on Imatinib. Blood, 116(21), 888. doi:10.1182/blood.v116.21.888.888

DOI
10.1182/blood.v116.21.888.888
Journal article

Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution.

Chakraverty, R., Orti, G., Roughton, M., Shen, J., Fielding, A., Kottaridis, P., . . . Mackinnon, S. (2010). Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution.. Blood, 116(16), 3080-3088. doi:10.1182/blood-2010-05-286856

DOI
10.1182/blood-2010-05-286856
Journal article

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.

Saglio, G., Kim, D. -W., Issaragrisil, S., le Coutre, P., Etienne, G., Lobo, C., . . . ENESTnd Investigators. (2010). Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.. The New England journal of medicine, 362(24), 2251-2259. doi:10.1056/nejmoa0912614

DOI
10.1056/nejmoa0912614
Journal article

High-density single nucleotide polymorphism array analysis and ASXL1 gene mutation screening in chronic myeloid leukemia during disease progression.

Boultwood, J., Perry, J., Zaman, R., Fernandez-Santamaria, C., Littlewood, T., Kusec, R., . . . Wainscoat, J. S. (2010). High-density single nucleotide polymorphism array analysis and ASXL1 gene mutation screening in chronic myeloid leukemia during disease progression.. Leukemia, 24(6), 1139-1145. doi:10.1038/leu.2010.65

DOI
10.1038/leu.2010.65
Journal article

Simultaneous determination of nilotinib, imatinib and its main metabolite (CGP-74588) in human plasma by ultra-violet high performance liquid chromatography

Davies, A., Hayes, A. K., Knight, K., Watmough, S. J., Pirmohamed, M., & Clark, R. E. (2010). Simultaneous determination of nilotinib, imatinib and its main metabolite (CGP-74588) in human plasma by ultra-violet high performance liquid chromatography. LEUKEMIA RESEARCH, 34(6), 702-707. doi:10.1016/j.leukres.2009.11.009

DOI
10.1016/j.leukres.2009.11.009
Journal article

European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy.

Burnett, A. K., Russell, N. H., Kell, J., Dennis, M., Milligan, D., Paolini, S., . . . Hills, R. K. (2010). European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28(14), 2389-2395. doi:10.1200/jco.2009.26.4242

DOI
10.1200/jco.2009.26.4242
Journal article

BCR-ABL1 tyrosine kinase activity at diagnosis, as determined via the pCrkL/CrkL ratio, is predictive of clinical outcome in chronic myeloid leukaemia

Lucas, C. M., Harris, R. J., Giannoudis, A., Knight, K., Watmough, S. J., & Clark, R. E. (2010). BCR-ABL1 tyrosine kinase activity at diagnosis, as determined via the pCrkL/CrkL ratio, is predictive of clinical outcome in chronic myeloid leukaemia. BRITISH JOURNAL OF HAEMATOLOGY, 149(3), 458-460. doi:10.1111/j.1365-2141.2009.08066.x

DOI
10.1111/j.1365-2141.2009.08066.x
Journal article

A Genome-wide screen identifies novel frequently methylated genes in leukemia and genes associated with clinical outcome in chronic myeloid leukaemia

Dunwell, T., Hesson, L., Rauch, T., Wang, L., Clark, R. E., Dallol, A., . . . Latif, F. (2010). A Genome-wide screen identifies novel frequently methylated genes in leukemia and genes associated with clinical outcome in chronic myeloid leukaemia. Molecular Cancer, 9, 44-55.

Journal article

Analysis of BCR-ABL1 tyrosine kinase domain mutational spectra in primitive chronic myeloid leukemia cells suggests a unique mutator phenotype

Grant, H., Jiang, X., Stebbing, J., Foroni, L., Craddock, C., Griffiths, M., . . . Woolfson, A. (2010). Analysis of BCR-ABL1 tyrosine kinase domain mutational spectra in primitive chronic myeloid leukemia cells suggests a unique mutator phenotype. LEUKEMIA, 24(10), 1817-1821. doi:10.1038/leu.2010.179

DOI
10.1038/leu.2010.179
Journal article

Diverging effects of HLA-DPB1 matching status on outcome following unrelated donor transplantation depending on disease stage and the degree of matching for other HLA alleles.

Shaw, B. E., Mayor, N. P., Russell, N. H., Apperley, J. F., Clark, R. E., Cornish, J., . . . Madrigal, J. A. (2010). Diverging effects of HLA-DPB1 matching status on outcome following unrelated donor transplantation depending on disease stage and the degree of matching for other HLA alleles.. Leukemia, 24(1), 58-65. doi:10.1038/leu.2009.239

DOI
10.1038/leu.2009.239
Journal article

EVI-1 oncogene expression predicts survival in chronic phase CML patients resistant to imatinib

Daghistani, M., Marin, D., Khorashad, J. S., May, P. C., Paliompeis, C., Milojkovic, D., . . . Reid, A. G. (2010). EVI-1 oncogene expression predicts survival in chronic phase CML patients resistant to imatinib. Blood, 116, 6014-6017.

Journal article

Naturally occurring CD4+ CD25+ FOXP3+ T regulatory cells are increased in chronic myeloid leukaemia patients with high BCR-ABL transcripts and can suppress anti-BCR-ABL responses

Rojas, J. M., Wang, L. H., Owen, S., Knight, K., Watmough, S., & Clark, R. E. (2010). Naturally occurring CD4+ CD25+ FOXP3+ T regulatory cells are increased in chronic myeloid leukaemia patients with high BCR-ABL transcripts and can suppress anti-BCR-ABL responses. Experimental Hematology, 38, 1209-1218.

Journal article

Nilotinib is superior to imatinib as first line therapy of chronic myeloid leukemia (CML): the ENESTnd study as a landmark on the path to cure in CML

Giles, F. J., Rosti, G., Beris, P., Clark, R. E., le Coutre, P., Mahon, F. -X., . . . Saglio, G. (2010). Nilotinib is superior to imatinib as first line therapy of chronic myeloid leukemia (CML): the ENESTnd study as a landmark on the path to cure in CML. Expert Reviews in Haematology, 3, 665-673.

Journal article

THE PRE-TREATMENT LEVELS OF PROTEIN PHOSPHATASE 2A (PP2A) AND ITS INHIBITOR SET CAN PREDICT PATIENTS DESTINED TO PROGRESS TO BLAST CRISIS OF CML

Lucas, C., Harris, R. J., Giannoudis, A., & Clark, R. (2010). THE PRE-TREATMENT LEVELS OF PROTEIN PHOSPHATASE 2A (PP2A) AND ITS INHIBITOR SET CAN PREDICT PATIENTS DESTINED TO PROGRESS TO BLAST CRISIS OF CML. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 95, 338. Retrieved from https://www.webofscience.com/

Journal article

The pCrKL/CrKL ratio at initial diagnosis is predictive of treatment outcome in chronic myeloid leukaemia

Lucas, C. M., Harris, R. J., Giannoudis, A., Knight, K., Watmough, S. J., & Clark, R. E. (2010). The pCrKL/CrKL ratio at initial diagnosis is predictive of treatment outcome in chronic myeloid leukaemia. British Journal of Haematology, 149, 158-160.

Journal article

2009

Chronic myeloid leukemia patients with the e13a2 <i>BCR</i>-<i>ABL</i> fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript

Lucas, C. M., Harris, R. J., Giannoudis, A., Davies, A., Knight, K., Watmough, S. J., . . . Clark, R. E. (2009). Chronic myeloid leukemia patients with the e13a2 <i>BCR</i>-<i>ABL</i> fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 94(10), 1362-1367. doi:10.3324/haematol.2009.009134

DOI
10.3324/haematol.2009.009134
Journal article

Favorable outcomes with alemtuzumab-conditioned unrelated donor stem cell transplantation in adults with high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in first complete remission.

Patel, B., Kirkland, K. E., Szydlo, R., Pearce, R. M., Clark, R. E., Craddock, C., . . . Marks, D. I. (2009). Favorable outcomes with alemtuzumab-conditioned unrelated donor stem cell transplantation in adults with high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in first complete remission.. Haematologica, 94(10), 1399-1406. doi:10.3324/haematol.2009.008649

DOI
10.3324/haematol.2009.008649
Journal article

Facts and uncertainties in monitoring treatment response in chronic myeloid leukaemia.

Clark, R. E. (2009). Facts and uncertainties in monitoring treatment response in chronic myeloid leukaemia.. Leukemia research, 33(9), 1151-1155. doi:10.1016/j.leukres.2009.04.001

DOI
10.1016/j.leukres.2009.04.001
Journal article

Soluble HLA/peptide monomers cross-linked with co-stimulatory antibodies onto a streptavidin core molecule efficiently stimulate antigen-specific T cell responses.

Rusakiewicz, S., Aubert, G., Clark, R. E., Madrigal, A. J., Dodi, A. I., & Travers, P. J. (2009). Soluble HLA/peptide monomers cross-linked with co-stimulatory antibodies onto a streptavidin core molecule efficiently stimulate antigen-specific T cell responses.. Cancer immunology, immunotherapy : CII, 58(9), 1459-1470. doi:10.1007/s00262-009-0711-x

DOI
10.1007/s00262-009-0711-x
Journal article

Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy.

Grimwade, D., Jovanovic, J. V., Hills, R. K., Nugent, E. A., Patel, Y., Flora, R., . . . Burnett, A. K. (2009). Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27(22), 3650-3658. doi:10.1200/jco.2008.20.1533

DOI
10.1200/jco.2008.20.1533
Journal article

T cell function in chronic myeloid leukemia and its treatment with tyrosine kinase inhibitors--clues from and for sarcoidosis.

Punekar, M., Thachil, J., Salim, R., Watmough, S., & Clark, R. E. (2009). T cell function in chronic myeloid leukemia and its treatment with tyrosine kinase inhibitors--clues from and for sarcoidosis.. Leukemia research, 33(7), e91-e92. doi:10.1016/j.leukres.2008.11.032

DOI
10.1016/j.leukres.2008.11.032
Journal article

A pilot study of continuous imatinib vs pulsed imatinib with or without G-CSF in CML patients who have achieved a complete cytogenetic response.

Drummond, M. W., Heaney, N., Kaeda, J., Nicolini, F. E., Clark, R. E., Wilson, G., . . . Holyoake, T. L. (2009). A pilot study of continuous imatinib vs pulsed imatinib with or without G-CSF in CML patients who have achieved a complete cytogenetic response.. Leukemia, 23(6), 1199-1201. doi:10.1038/leu.2009.43

DOI
10.1038/leu.2009.43
Journal article

Nilotinib concentration in cell lines and primary CD34<SUP>+</SUP> chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters

Davies, A., Jordanides, N. E., Giannoudis, A., Lucas, C. M., Hatziieremia, S., Harris, R. J., . . . Mountford, J. C. (2009). Nilotinib concentration in cell lines and primary CD34<SUP>+</SUP> chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters. LEUKEMIA, 23(11), 1999-2006. doi:10.1038/leu.2009.166

DOI
10.1038/leu.2009.166
Journal article

2008

Nilotinib concentration in Cell Lines and CML CD34+ Cells Is Not Mediated by Active Uptake or Efflux by Major Drug Transporters

Mountford, J., Davies, A., Jordanides, N. E., Giannoudis, A., Lucas, C. M., Hatziieremia, S., . . . Clark, R. E. (2008). Nilotinib concentration in Cell Lines and CML CD34+ Cells Is Not Mediated by Active Uptake or Efflux by Major Drug Transporters. Blood, 112(11), 3205. doi:10.1182/blood.v112.11.3205.3205

DOI
10.1182/blood.v112.11.3205.3205
Journal article

Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia

Giannoudis, A., Davies, A., Lucas, C. M., Harris, R. J., Pirmohamed, M., & Clark, R. E. (2008). Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia. BLOOD, 112(8), 3348-3354. doi:10.1182/blood-2007-10-116236

DOI
10.1182/blood-2007-10-116236
Journal article

The harvest and use of autologous back-up grafts for graft failure or severe GVHD after allogeneic hematopoietic stem cell transplantation: a survey of the European Group for Blood and Marrow Transplantation.

Stelljes, M., van Biezen, A., Slavin, S., Olavarria, E., Clark, R. E., Nagler, A., . . . complications subcommittee of the Chronic Leukemia Working Party. (2008). The harvest and use of autologous back-up grafts for graft failure or severe GVHD after allogeneic hematopoietic stem cell transplantation: a survey of the European Group for Blood and Marrow Transplantation.. Bone marrow transplantation, 42(11), 739-742. doi:10.1038/bmt.2008.254

DOI
10.1038/bmt.2008.254
Journal article

Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia

Clark, R. E., Davies, A., Pirmohamed, M., & Giannoudis, A. (2008). Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia. LEUKEMIA & LYMPHOMA, 49(4), 639-642. doi:10.1080/10428190701858823

DOI
10.1080/10428190701858823
Journal article

Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia

Wang, L., Giannoudis, A., Lane, S., Williamson, P., Pirmohamed, M., & Clark, R. E. (2008). Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. CLINICAL PHARMACOLOGY & THERAPEUTICS, 83(2), 258-264. doi:10.1038/sj.clpt.6100268

DOI
10.1038/sj.clpt.6100268
Journal article

A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials

Lucas, C. M., Wang, L., Austin, G. M., Knight, K., Watmough, S. J., Shwe, K. H., . . . Clark, R. E. (2008). A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials. LEUKEMIA, 22(10), 1963-1966. doi:10.1038/leu.2008.225

DOI
10.1038/leu.2008.225
Journal article

Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia

Wang, L., Giannoudis, A., Lane, S., Williamson, P., Pirmohamed, M., & Clark, R. E. (2008). Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. Clinical Pharmacology and Therapeutics, 83(2), 258-264. doi:10.1038/sj.clpt.6100268

DOI
10.1038/sj.clpt.6100268
Journal article

Immunotherapy in chronic myeloid leukemia

Clark, R. E. (2008). Immunotherapy in chronic myeloid leukemia. In Chronic Myeloproliferative Disorders (pp. 118-125).

Chapter

2007

Evidence that a BCR-ABL fusion peptide does not induce lymphocyte proliferation or cytokine production in vitro.

Abu-Eisha, H. M., Butt, N. M., Clark, R. E., Christmas, S. E., & Christmas, S. E. (2007). Evidence that a BCR-ABL fusion peptide does not induce lymphocyte proliferation or cytokine production in vitro.. Leukemia research, 31(12), 1675-1681. doi:10.1016/j.leukres.2007.01.007

DOI
10.1016/j.leukres.2007.01.007
Journal article

Characterisation of Nilotinib Transport in Chronic Myeloid Leukaemia Cells.

Davies, A., Giannoudis, A., Lucas, C. M., Harris, R. J., Manley, P. W., Pirmohamed, M., & Clark, R. E. (2007). Characterisation of Nilotinib Transport in Chronic Myeloid Leukaemia Cells.. Blood, 110(11), 2364. doi:10.1182/blood.v110.11.2364.2364

DOI
10.1182/blood.v110.11.2364.2364
Journal article

Unlike imatinib, dasatinib uptake into chronic myeloid leukaemia cells is independent of hOCT1 expression

Giannoudis, A., Davies, A., Lucas, C. M., Harris, R. J., Pirmohamed, M., & Clark, R. E. (2007). Unlike imatinib, dasatinib uptake into chronic myeloid leukaemia cells is independent of hOCT1 expression. In BLOOD Vol. 110 (pp. 1013A-1014A). doi:10.1182/blood.V110.11.3458.3458

DOI
10.1182/blood.V110.11.3458.3458
Conference Paper

Immunotherapeutic strategies in chronic myeloid leukemia.

Clark, R. E. (2007). Immunotherapeutic strategies in chronic myeloid leukemia.. Current hematologic malignancy reports, 2(2), 89-94. doi:10.1007/s11899-007-0013-3

DOI
10.1007/s11899-007-0013-3
Journal article

Clinical evaluation of BCR-ABL peptide immunisation in chronic myeloid leukaemia: results of the EPIC study.

Rojas, J. M., Knight, K., Wang, L., & Clark, R. E. (2007). Clinical evaluation of BCR-ABL peptide immunisation in chronic myeloid leukaemia: results of the EPIC study.. Leukemia, 21(11), 2287-2295. doi:10.1038/sj.leu.2404858

DOI
10.1038/sj.leu.2404858
Journal article

Dasatinib: a new therapy for myeloproliferative disorders

Clark, R. E. (2007). Dasatinib: a new therapy for myeloproliferative disorders. Myeloproliferative Disorders in Practice, 1, 3-5.

Journal article

Definition of the breakpoint fusion peptides for HLA-B8 as well as HLA-A3 in CML cells.

Dodi, I. A., Rusakiewicz, S., Aubert, G., Clark, R. E., Creaser, C., Bonner, P., . . . Madrigal, J. A. (2007). Definition of the breakpoint fusion peptides for HLA-B8 as well as HLA-A3 in CML cells.. In J. A. Hansen (Ed.), Immunobiology of the Human MHC; proceedings of 13th International workshop and congress. Vol II. (pp. 275-280). Seattle: International Histocompatibily Workshop Group press.

Chapter

Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group.

Ruutu, T., Barosi, G., Benjamin, R. J., Clark, R. E., George, J. N., Gratwohl, A., . . . European LeukemiaNet. (2007). Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group.. Haematologica, 92(1), 95-100. doi:10.3324/haematol.10699

DOI
10.3324/haematol.10699
Journal article

2006

Autologous stem cell transplantation for progressive multiple sclerosis: update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database.

Saccardi, R., Kozak, T., Bocelli-Tyndall, C., Fassas, A., Kazis, A., Havrdova, E., . . . Autoimmune Diseases Working Party of EBMT. (2006). Autologous stem cell transplantation for progressive multiple sclerosis: update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database.. Multiple sclerosis (Houndmills, Basingstoke, England), 12(6), 814-823. doi:10.1177/1352458506071301

DOI
10.1177/1352458506071301
Journal article

A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy.

Knapper, S., Burnett, A. K., Littlewood, T., Kell, W. J., Agrawal, S., Chopra, R., . . . Small, D. (2006). A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy.. Blood, 108(10), 3262-3270. doi:10.1182/blood-2006-04-015560

DOI
10.1182/blood-2006-04-015560
Journal article

Clinical and functional evidence that drug transporter expression dictates the response to imatinib in chronic myeloid leukaemia.

Wang, L., Giannoudis, A., Lane, S., Williamson, P. R., Pirmohamed, M., & Clark, R. E. (2006). Clinical and functional evidence that drug transporter expression dictates the response to imatinib in chronic myeloid leukaemia.. In BLOOD Vol. 108 (pp. 608A-609A). doi:10.1182/blood.V108.11.2145.2145

DOI
10.1182/blood.V108.11.2145.2145
Conference Paper

The outcome of sibling and unrelated donor allogeneic stem cell transplantation in adult patients with acute myeloid leukemia in first remission who were initially refractory to first induction chemotherapy.

Cook, G., Clark, R. E., Crawley, C., Mackinnon, S., Russell, N., Thomson, K., . . . Marks, D. I. (2006). The outcome of sibling and unrelated donor allogeneic stem cell transplantation in adult patients with acute myeloid leukemia in first remission who were initially refractory to first induction chemotherapy.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 12(3), 293-300. doi:10.1016/j.bbmt.2005.10.019

DOI
10.1016/j.bbmt.2005.10.019
Journal article

The role of serial <i>BCR-ABL</i> transcript monitoring in predicting the emergence of <i>BCR-ABL</i> kinase mutations in imatinib-treated patients with chronic myeloid leukemia

Wang, L. H., Knight, K., Lucas, C., & Clark, R. E. (2006). The role of serial <i>BCR-ABL</i> transcript monitoring in predicting the emergence of <i>BCR-ABL</i> kinase mutations in imatinib-treated patients with chronic myeloid leukemia. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 91(2), 235-239. Retrieved from https://www.webofscience.com/

Journal article

2005

Management of chronic myeloid leukaemia in relapse following donor lymphocyte infusion induced remission: a retrospective study of the Clinical Trials Committee of the British Society of Blood & Marrow Transplantation (BSBMT).

Cummins, M., Cwynarski, K., Marktel, S., Dazzi, F., Cavenagh, J., Clark, R. E., . . . Clinical Trials Committee British Society of Blood & Marrow Transplantation (BSBMT). (2005). Management of chronic myeloid leukaemia in relapse following donor lymphocyte infusion induced remission: a retrospective study of the Clinical Trials Committee of the British Society of Blood & Marrow Transplantation (BSBMT).. Bone marrow transplantation, 36(12), 1065-1069. doi:10.1038/sj.bmt.1705180

DOI
10.1038/sj.bmt.1705180
Journal article

Circulating bcr-abl-specific CD8+ T cells in chronic myeloid leukemia patients

Butt, N. M., Rojas, J. M., Wang, L., Christmas, S. E., Abu-Eisha, H. M., & Clark, R. E. (2005). Circulating bcr-abl-specific CD8+ T cells in chronic myeloid leukemia patients. Haematologica, 90(10), 1315-1323. Retrieved from http://www.haematologica.org/journal/2005/901315.pdf

Journal article

Circulating bcr-abl-specific CD8+ T cells in chronic myeloid leukemia patients and healthy subjects.

Butt, N. M., Rojas, J. M., Wang, L., Christmas, S. E., Abu-Eisha, H. M., & Clark, R. E. (2005). Circulating bcr-abl-specific CD8+ T cells in chronic myeloid leukemia patients and healthy subjects.. Haematologica, 90(10), 1315-1323.

Journal article

hOCT 1 and resistance to imatinib

Crossman, L. C., Druker, B. J., & Deininger, M. W. N. (2005). hOCT 1 and resistance to imatinib. BLOOD, 106(3), 1133-1134. doi:10.1182/blood-2005-02-0694

DOI
10.1182/blood-2005-02-0694
Journal article

Ancestim associated with Filgrastim and/or chemotherapy can improve blood progenitor yields in patients who previously failed mobilisation.

Mijovic, A., Russell, N., Clark, R. E., Morris, T. C. M., Browne, P., Crown, J., . . . Mufti, G. J. (2005). Ancestim associated with Filgrastim and/or chemotherapy can improve blood progenitor yields in patients who previously failed mobilisation.. Bone marrow transplantation, 35(10), 1019. doi:10.1038/sj.bmt.1704950

DOI
10.1038/sj.bmt.1704950
Journal article

The immune response to chronic myeloid leukaemia

Clark, R. E. (2005). The immune response to chronic myeloid leukaemia. In R. F. Romero (Ed.), Focus on Leukemia Research (pp. 27-60). New York: Nova Science Publishers, Inc.

Chapter

Uncertainties in the use of imatinib in chronic myeloid leukaemia

Clark, R. E., & Wang, L. (2005). Uncertainties in the use of imatinib in chronic myeloid leukaemia. British Journal of Cancer Management, 1, 11-14.

Journal article

2004

Active transport of imatinib into and out of cells: implications for drug resistance

Thomas, J., Wang, L. H., Clark, R. E., & Pirmohamed, M. (2004). Active transport of imatinib into and out of cells: implications for drug resistance. BLOOD, 104(12), 3739-3745. doi:10.1182/blood-2003-12-4276

DOI
10.1182/blood-2003-12-4276
Journal article

A randomized study (WOS MM1) comparing the oral regime Z-Dex (idarubicin and dexamethasone) with vincristine, adriamycin and dexamethasone as induction therapy for newly diagnosed patients with multiple myeloma.

Cook, G., Clark, R. E., Morris, T. C. M., Robertson, M., Lucie, N. P., Anderson, S., . . . Franklin, I. M. (2004). A randomized study (WOS MM1) comparing the oral regime Z-Dex (idarubicin and dexamethasone) with vincristine, adriamycin and dexamethasone as induction therapy for newly diagnosed patients with multiple myeloma.. British journal of haematology, 126(6), 792-798. doi:10.1111/j.1365-2141.2004.05127.x

DOI
10.1111/j.1365-2141.2004.05127.x
Journal article

Successful outcome of pregnancy in chronic myeloid leukaemia treated with imatinib.

Heartin, E., Walkinshaw, S., & Clark, R. E. (2004). Successful outcome of pregnancy in chronic myeloid leukaemia treated with imatinib.. Leukemia & lymphoma, 45(6), 1307-1308. doi:10.1080/10428190310001645195

DOI
10.1080/10428190310001645195
Journal article

Dendritic cells become BCR-ABL negative in chronic myeloid leukaemia patients successfully treated with imatinib.

Wang, L., Butt, N. M., Atherton, M. G., & Clark, R. E. (2004). Dendritic cells become BCR-ABL negative in chronic myeloid leukaemia patients successfully treated with imatinib.. Leukemia, 18(5), 1025-1027. doi:10.1038/sj.leu.2403342

DOI
10.1038/sj.leu.2403342
Journal article

BCR-ABL-specific T cells can be detected in healthy donors and in chronic myeloid leukemia patients following allogeneic stem cell transplantation.

Butt, N. M., Wang, L., Abu-Eisha, H. M., Christmas, S. E., & Clark, R. E. (2004). BCR-ABL-specific T cells can be detected in healthy donors and in chronic myeloid leukemia patients following allogeneic stem cell transplantation.. Blood, 103(8), 3245. doi:10.1182/blood-2003-11-4086

DOI
10.1182/blood-2003-11-4086
Journal article

Active transport of imatinib into and out of cells: implications for drug resistance

Thomas, J., Wang, L., Clark, R. E., & Pirmohamed, M. (2004). Active transport of imatinib into and out of cells: implications for drug resistance. Blood, 104(12), 3739-3745. doi:10.1182/blood-2003-12-4276

DOI
10.1182/blood-2003-12-4276
Journal article

2003

A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia.

Kell, W. J., Burnett, A. K., Chopra, R., Yin, J. A. L., Clark, R. E., Rohatiner, A., . . . Milligan, D. W. (2003). A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia.. Blood, 102(13), 4277-4283. doi:10.1182/blood-2003-05-1620

DOI
10.1182/blood-2003-05-1620
Journal article

Autografting as a risk factor for persisting iron overload in long-term survivors of acute myeloid leukaemia.

Butt, N. M., & Clark, R. E. (2003). Autografting as a risk factor for persisting iron overload in long-term survivors of acute myeloid leukaemia.. Bone marrow transplantation, 32(9), 909-913. doi:10.1038/sj.bmt.1704244

DOI
10.1038/sj.bmt.1704244
Journal article

Mobilization of Ph chromosome-negative peripheral blood stem cells in chronic myeloid leukaemia patients with imatinib mesylate-induced complete cytogenetic remission.

Drummond, M. W., Marin, D., Clark, R. E., Byrne, J. L., Holyoake, T. L., Lennard, A., & United Kingdom Chronic Myeloid Leukaemia (UK CML) Working Party. (2003). Mobilization of Ph chromosome-negative peripheral blood stem cells in chronic myeloid leukaemia patients with imatinib mesylate-induced complete cytogenetic remission.. British journal of haematology, 123(3), 479-483. doi:10.1046/j.1365-2141.2003.04599.x

DOI
10.1046/j.1365-2141.2003.04599.x
Journal article

Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: influence of dose and stem cell source shows better outcome with rich marrow.

Gorin, N. C., Labopin, M., Rocha, V., Arcese, W., Beksac, M., Gluckman, E., . . . European Cooperative Group for Blood and Marrow Transplantation Acute Leukemia Working Party. (2003). Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: influence of dose and stem cell source shows better outcome with rich marrow.. Blood, 102(8), 3043-3051. doi:10.1182/blood-2003-03-0665

DOI
10.1182/blood-2003-03-0665
Journal article

BCR-ABL with an e6a2 fusion in a CML patient diagnosed in blast crisis.

Schultheis, B., Wang, L., Clark, R. E., & Melo, J. V. (2003). BCR-ABL with an e6a2 fusion in a CML patient diagnosed in blast crisis.. Leukemia, 17(10), 2054-2055. doi:10.1038/sj.leu.2403079

DOI
10.1038/sj.leu.2403079
Journal article

Imatinib improves but may not fully reverse the poor prognosis of patients with CML with derivative chromosome 9 deletions.

Huntly, B. J. P., Guilhot, F., Reid, A. G., Vassiliou, G., Hennig, E., Franke, C., . . . Deininger, M. W. N. (2003). Imatinib improves but may not fully reverse the poor prognosis of patients with CML with derivative chromosome 9 deletions.. Blood, 102(6), 2205-2212. doi:10.1182/blood-2002-09-2763

DOI
10.1182/blood-2002-09-2763
Journal article

CD34 positive selection as prophylaxis against graft versus host disease in allogeneic peripheral blood stem cell transplantation.

Butt, N. M., McGinnity, N., & Clark, R. E. (2003). CD34 positive selection as prophylaxis against graft versus host disease in allogeneic peripheral blood stem cell transplantation.. Leukemia & lymphoma, 44(9), 1509-1513. doi:10.1080/1042819031000083019

DOI
10.1080/1042819031000083019
Journal article

Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia.

Olavarria, E., Ottmann, O. G., Deininger, M., Clark, R. E., Bandini, G., Byrne, J., . . . Chronic Leukaemia Working Party of the European Group of Bone and Marrow Transplantation (EBMT). (2003). Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia.. Leukemia, 17(9), 1707-1712. doi:10.1038/sj.leu.2403068

DOI
10.1038/sj.leu.2403068
Journal article

A phase III, randomized, double-blind, placebo-controlled, multinational trial of iseganan for the prevention of oral mucositis in patients receiving stomatotoxic chemotherapy (PROMPT-CT trial).

Giles, F. J., Miller, C. B., Hurd, D. D., Wingard, J. R., Fleming, T. R., Sonis, S. T., . . . PROMPT-CT Trial Investigators. (2003). A phase III, randomized, double-blind, placebo-controlled, multinational trial of iseganan for the prevention of oral mucositis in patients receiving stomatotoxic chemotherapy (PROMPT-CT trial).. Leukemia & lymphoma, 44(7), 1165-1172. doi:10.1080/1042819031000079159

DOI
10.1080/1042819031000079159
Journal article

CpG oligodeoxynucleotide 5mer-induced apoptosis in MOLT-4 leukaemia cells does not require caspase 3 or new protein synthesis

Tidd, D. M., Broughton, C. M., & Clark, R. E. (2003). CpG oligodeoxynucleotide 5mer-induced apoptosis in MOLT-4 leukaemia cells does not require caspase 3 or new protein synthesis. NUCLEIC ACIDS RESEARCH, 31(9), 2297-2304. doi:10.1093/nar/gkg334

DOI
10.1093/nar/gkg334
Journal article

A prospective, randomized trial for the prevention of mucositis in patients undergoing hematopoietic stem cell transplantation.

Papas, A. S., Clark, R. E., Martuscelli, G., O'Loughlin, K. T., Johansen, E., & Miller, K. B. (2003). A prospective, randomized trial for the prevention of mucositis in patients undergoing hematopoietic stem cell transplantation.. Bone marrow transplantation, 31(8), 705-712. doi:10.1038/sj.bmt.1703870

DOI
10.1038/sj.bmt.1703870
Journal article

The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia.

Wang, L., Pearson, K., Ferguson, J. E., & Clark, R. E. (2003). The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia.. British journal of haematology, 120(6), 990-999. doi:10.1046/j.1365-2141.2003.04200.x

DOI
10.1046/j.1365-2141.2003.04200.x
Journal article

Successful mobilisation of Ph chromosome-negative peripheral blood stem cells in chronic myeloid leukemia patients with imatinib mesylate (Gleevec®)-induced complete cytogenetic remission

Drummond, M. W., Marin, D., Clark, R. E., Byrne, J., Goldman, J. M., Holyoake, T. L., & Lennard, A. (2003). Successful mobilisation of Ph chromosome-negative peripheral blood stem cells in chronic myeloid leukemia patients with imatinib mesylate (Gleevec®)-induced complete cytogenetic remission. British Journal of Haematology, 123(3), 479-483.

Journal article

2002

Chronic lymphocytic leukaemia developing in the course of chronic myeloid leukaemia.

Salim, R., Wang, L., Lin, K., & Clark, R. E. (2002). Chronic lymphocytic leukaemia developing in the course of chronic myeloid leukaemia.. Leukemia & lymphoma, 43(11), 2225-2227. doi:10.1080/1042819021000016140a

DOI
10.1080/1042819021000016140a
Journal article

Serial monitoring of BCR-ABL by peripheral blood real-time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia.

Wang, L., Pearson, K., Pillitteri, L., Ferguson, J. E., & Clark, R. E. (2002). Serial monitoring of BCR-ABL by peripheral blood real-time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia.. British journal of haematology, 118(3), 771-777. doi:10.1046/j.1365-2141.2002.03705.x

DOI
10.1046/j.1365-2141.2002.03705.x
Journal article

The post-transplant cytogenetic response to interferon is a major determinant of survival after autologous stem cell transplantation for chronic myeloid leukaemia in chronic phase.

Olavarria, E., Reiffers, J., Boque, C., Sureda, A., Meloni, G., Michallet, M., . . . Apperley, J. F. (2002). The post-transplant cytogenetic response to interferon is a major determinant of survival after autologous stem cell transplantation for chronic myeloid leukaemia in chronic phase.. British journal of haematology, 118(3), 762-770. doi:10.1046/j.1365-2141.2002.03600.x

DOI
10.1046/j.1365-2141.2002.03600.x
Journal article

e19a2-positive chronic myeloid leukaemia with BCR exon e16-deleted transcripts.

Wang, L., Seale, J., Woodcock, B. E., & Clark, R. E. (2002). e19a2-positive chronic myeloid leukaemia with BCR exon e16-deleted transcripts.. Leukemia, 16(8), 1562-1563. doi:10.1038/sj.leu.2402600

DOI
10.1038/sj.leu.2402600
Journal article

Not so NICE for CML

Goldman, J., Apperley, J., Clark, R., Green, T., Holyoake, T., O'Brien, S., & Shepherd, P. (2002). Not so NICE for CML. LANCET, 359(9322), 2036. doi:10.1016/S0140-6736(02)08796-2

DOI
10.1016/S0140-6736(02)08796-2
Journal article

Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants.

Ljungman, P., de La Camara, R., Milpied, N., Volin, L., Russell, C. A., Crisp, A., . . . Valacyclovir International Bone Marrow Transplant Study Group. (2002). Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants.. Blood, 99(8), 3050-3056. doi:10.1182/blood.v99.8.3050

DOI
10.1182/blood.v99.8.3050
Journal article

Bone turnover following autologous transplantation in multiple myeloma.

Clark, R. E., & Fraser, W. D. (2002). Bone turnover following autologous transplantation in multiple myeloma.. Leukemia & lymphoma, 43(3), 511-516. doi:10.1080/10428190290011985

DOI
10.1080/10428190290011985
Journal article

Position paper on imatinib mesylate in chronic myeloid leukaemia

O'Brien, S. G., Rule, S. A. J., Milligan, D. W., Johnson, S., Marcus, R., Goldman, J. M., . . . Smith, G. (2002). Position paper on imatinib mesylate in chronic myeloid leukaemia. British Journal of Haematology, 119, 268-272.

Journal article

2001

Laparoscopically assisted splenectomy for idiopathic thrombocytopenic purpura in a previously conserved spleen.

Isherwood, P., Hershman, M. J., Hartley, M., & Clark, R. E. (2001). Laparoscopically assisted splenectomy for idiopathic thrombocytopenic purpura in a previously conserved spleen.. Hospital medicine (London, England : 1998), 62(11), 708-709.

Journal article

Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein.

Clark, R. E., Dodi, I. A., Hill, S. C., Lill, J. R., Aubert, G., Macintyre, A. R., . . . Madrigal, J. A. (2001). Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein.. Blood, 98(10), 2887-2893. doi:10.1182/blood.v98.10.2887

DOI
10.1182/blood.v98.10.2887
Journal article

Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial.

Goldstone, A. H., Burnett, A. K., Wheatley, K., Smith, A. G., Hutchinson, R. M., Clark, R. E., & Medical Research Council Adult Leukemia Working Party. (2001). Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial.. Blood, 98(5), 1302-1311. doi:10.1182/blood.v98.5.1302

DOI
10.1182/blood.v98.5.1302
Journal article

HLA-A3 increases and HLA-DR1 decreases the risk of acute graft-versus-host disease after HLA-matched sibling bone marrow transplantation for chronic myelogenous leukaemia.

Clark, R. E., Hermans, J., Madrigal, A., Nachbaur, D., Kropshofer, G., Gratwohl, A., . . . Chronic Leukaemia Working Party of the European Group of Blood and Bone Marrow Transplantation. (2001). HLA-A3 increases and HLA-DR1 decreases the risk of acute graft-versus-host disease after HLA-matched sibling bone marrow transplantation for chronic myelogenous leukaemia.. British journal of haematology, 114(1), 36-41. doi:10.1046/j.1365-2141.2001.02897.x

DOI
10.1046/j.1365-2141.2001.02897.x
Journal article

High frequency of positive surveillance for cytomegalovirus (CMV) by PCR in allograft recipients at low risk of CMV.

Butt, N. M., & Clark, R. E. (2001). High frequency of positive surveillance for cytomegalovirus (CMV) by PCR in allograft recipients at low risk of CMV.. Bone marrow transplantation, 27(6), 615-619. doi:10.1038/sj.bmt.1702836

DOI
10.1038/sj.bmt.1702836
Journal article

BCR-ABL fusion peptides and cytotoxic T cells in chronic myeloid leukaemia.

Clark, R. E., & Christmas, S. E. (2001). BCR-ABL fusion peptides and cytotoxic T cells in chronic myeloid leukaemia.. Leukemia & lymphoma, 42(5), 871-880. doi:10.3109/10428190109097706

DOI
10.3109/10428190109097706
Journal article

Characterisation of HLA-A3 restricted peptide from the BCR-ABL fusion protein of the Philadelphia chromosome using Nano-electrospray ion trap mass spectrometry

Creaser, C. S., Lill, J. R., Bonner, P. L. R., Hill, S. C., Rees, R. C., Christmas, S. E., . . . Madrigal, J. A. (2001). Characterisation of HLA-A3 restricted peptide from the BCR-ABL fusion protein of the Philadelphia chromosome using Nano-electrospray ion trap mass spectrometry. Advances in Mass Spectrometry, 15, 637-638.

Journal article

Expression of c-myc is not critical for cell proliferation in established human leukemia lines

Tidd, D. M., Giles, R. V., Broughton, C. M., & Clark, R. E. (2001). Expression of c-myc is not critical for cell proliferation in established human leukemia lines. Biomed Central (BMC) Molecular Biology, 2, 13. Retrieved from http://www.biomedcentral.com/1471-2199/2/13/

Journal article

2000

Biochemical markers of bone turnover following high-dose chemotherapy and autografting in multiple myeloma.

Clark, R. E., Flory, A. J., Ion, E. M., Woodcock, B. E., Durham, B. H., & Fraser, W. D. (2000). Biochemical markers of bone turnover following high-dose chemotherapy and autografting in multiple myeloma.. Blood, 96(8), 2697-2702.

Journal article

b3a2 BCR-ABL fusion peptides as targets for cytotoxic T cells in chronic myeloid leukaemia.

Norbury, L. C., Clark, R. E., Christmas, S. E., & Christmas, S. E. (2000). b3a2 BCR-ABL fusion peptides as targets for cytotoxic T cells in chronic myeloid leukaemia.. British journal of haematology, 109(3), 616-621. doi:10.1046/j.1365-2141.2000.02090.x

DOI
10.1046/j.1365-2141.2000.02090.x
Journal article

Oligodeoxynucleotide 5mers containing a 5′-CpG induce apoptosis through a mitochondrial mechanism in T lymphocytic leukaemia cells

Tidd, D. M., Spiller, D. G., Broughton, C. M., Norbury, L. C., Clark, R. E., & Giles, R. V. (2000). Oligodeoxynucleotide 5mers containing a 5′-CpG induce apoptosis through a mitochondrial mechanism in T lymphocytic leukaemia cells. NUCLEIC ACIDS RESEARCH, 28(11), 2242-2250. doi:10.1093/nar/28.11.2242

DOI
10.1093/nar/28.11.2242
Journal article

Antisense therapeutics in chronic myeloid leukaemia: the promise, the progress and the problems.

Clark, R. E. (2000). Antisense therapeutics in chronic myeloid leukaemia: the promise, the progress and the problems.. Leukemia, 14(3), 347-355. doi:10.1038/sj.leu.2401677

DOI
10.1038/sj.leu.2401677
Journal article

1999

Clinical use of streptolysin-O to facilitate antisense oligodeoxyribonucleotide delivery for purging autografts in chronic myeloid leukaemia

Clark, R. E., Grzybowski, J., Broughton, C. M., Pender, N. T., Spiller, D. G., Brammer, C. G., . . . Tidd, D. M. (1999). Clinical use of streptolysin-O to facilitate antisense oligodeoxyribonucleotide delivery for purging autografts in chronic myeloid leukaemia. BONE MARROW TRANSPLANTATION, 23(12), 1303-1308. doi:10.1038/sj.bmt.1701801

DOI
10.1038/sj.bmt.1701801
Journal article

Chemotherapy-induced acral erythema (CIAE) with bullous reaction.

Azurdia, R. M., Clark, R. E., & Friedmann, P. S. (1999). Chemotherapy-induced acral erythema (CIAE) with bullous reaction.. Clinical and experimental dermatology, 24(2), 64-66. doi:10.1046/j.1365-2230.1999.00419.x

DOI
10.1046/j.1365-2230.1999.00419.x
Journal article

Antisense morpholino oligonucleotide analog induces missplicing of C-myc mRNA.

Giles, R. V., Spiller, D. G., Clark, R. E., & Tidd, D. M. (1999). Antisense morpholino oligonucleotide analog induces missplicing of C-myc mRNA.. Antisense & nucleic acid drug development, 9(2), 213-220. doi:10.1089/oli.1.1999.9.213

DOI
10.1089/oli.1.1999.9.213
Journal article

Antisense morpholino oligonucleotide analogue induces mis-splicing of c-MYC mRNA

Giles, R. V., Spiller, D. G., Clark, R. E., & Tidd, D. M. (1999). Antisense morpholino oligonucleotide analogue induces mis-splicing of c-MYC mRNA. Antisense & Nucleic Acid Drug Development, 9, 213-220.

Journal article

Identification of a good c-myc antisense oligodeoxynucleotide target site and the inactivity at this site of novel NCH triplet--targeting ribozymes.

Giles, R. V., Spiller, D. G., Clark, R. E., & Tidd, D. M. (1999). Identification of a good c-myc antisense oligodeoxynucleotide target site and the inactivity at this site of novel NCH triplet--targeting ribozymes.. Nucleosides & nucleotides, 18(9), 1935-1944. doi:10.1080/07328319908044855

DOI
10.1080/07328319908044855
Journal article

1998

Bone-marrow donation by mentally incapable adults.

Clark, R. E. (1998). Bone-marrow donation by mentally incapable adults.. Lancet (London, England), 352(9143), 1847-1848. doi:10.1016/s0140-6736(98)04378-5

DOI
10.1016/s0140-6736(98)04378-5
Journal article

Previous treatment predicts the efficiency of blood progenitor cell mobilisation: validation of a chemotherapy scoring system.

Clark, R. E., & Brammer, C. G. (1998). Previous treatment predicts the efficiency of blood progenitor cell mobilisation: validation of a chemotherapy scoring system.. Bone marrow transplantation, 22(9), 859-863. doi:10.1038/sj.bmt.1701461

DOI
10.1038/sj.bmt.1701461
Journal article

Autologous transplantation in chronic myeloid leukaemia using peripheral blood stem cells.

Singer, I. O., Franklin, I. M., Clark, R. E., Chalmers, E. A., Kelsey, S. M., Newland, A. C., . . . Tansey, P. J. (1998). Autologous transplantation in chronic myeloid leukaemia using peripheral blood stem cells.. British journal of haematology, 102(5), 1359-1362. doi:10.1046/j.1365-2141.1998.00897.x

DOI
10.1046/j.1365-2141.1998.00897.x
Journal article

Comparison of a patient-controlled analgesia system with continuous infusion for administration of diamorphine for mucositis.

Pillitteri, L. C., & Clark, R. E. (1998). Comparison of a patient-controlled analgesia system with continuous infusion for administration of diamorphine for mucositis.. Bone marrow transplantation, 22(5), 495-498. doi:10.1038/sj.bmt.1701370

DOI
10.1038/sj.bmt.1701370
Journal article

Abnormalities of the ETV6 gene occur in the majority of patients with aberrations of the short arm of chromosome 12: a combined PCR and Southern blotting analysis.

O'Connor, H. E., Butler, T. A., Clark, R., Swanton, S., Harrison, C. J., Secker-Walker, L. M., & Foroni, L. (1998). Abnormalities of the ETV6 gene occur in the majority of patients with aberrations of the short arm of chromosome 12: a combined PCR and Southern blotting analysis.. Leukemia, 12(7), 1099-1106. doi:10.1038/sj.leu.2401070

DOI
10.1038/sj.leu.2401070
Journal article

Improving the Intracellular Delivery and Molecular Efficacy of Antisense Oligonucleotides in Chronic Myeloid Leukemia Cells: A Comparison of Streptolysin-O Permeabilization, Electroporation, and Lipophilic Conjugation

Spiller, D. G., Giles, R. V., Grzybowski, J., Tidd, D. M., & Clark, R. E. (1998). Improving the Intracellular Delivery and Molecular Efficacy of Antisense Oligonucleotides in Chronic Myeloid Leukemia Cells: A Comparison of Streptolysin-O Permeabilization, Electroporation, and Lipophilic Conjugation. Blood, 91(12), 4738-4746. doi:10.1182/blood.v91.12.4738

DOI
10.1182/blood.v91.12.4738
Journal article

Improving the intracellular delivery and molecular efficacy of antisense oligonucleotides in chronic myeloid leukemia cells: a comparison of streptolysin-O permeabilization, electroporation, and lipophilic conjugation.

Spiller, D. G., Giles, R. V., Grzybowski, J., Tidd, D. M., & Clark, R. E. (1998). Improving the intracellular delivery and molecular efficacy of antisense oligonucleotides in chronic myeloid leukemia cells: a comparison of streptolysin-O permeabilization, electroporation, and lipophilic conjugation.. Blood, 91(12), 4738-4746.

Journal article

Selecting optimal oligonucleotide composition for maximal antisense effect following streptolysin O-mediated delivery into human leukaemia cells.

Giles, R. V., Spiller, D. G., Grzybowski, J., Clark, R. E., Nicklin, P., & Tidd, D. M. (1998). Selecting optimal oligonucleotide composition for maximal antisense effect following streptolysin O-mediated delivery into human leukaemia cells.. Nucleic acids research, 26(7), 1567-1575. doi:10.1093/nar/26.7.1567

DOI
10.1093/nar/26.7.1567
Journal article

Maximising antisense oligonucleotide efficacy: Selecting optimal structures for Streptolysin O delivery into human leukaemia cells

Giles, R. V., Spiller, D. G., Grzybowski, J., Clark, R. E., Nicklin, P., & Tidd, D. M. (1998). Maximising antisense oligonucleotide efficacy: Selecting optimal structures for Streptolysin O delivery into human leukaemia cells. Nucleic Acids Research, 26, 1567-1575.

Journal article

The influence of target protein half-life on the effectiveness of antisense oligonucleotide analog-mediated biologic responses

Spiller, D. G., Giles, R. V., Broughton, C. M., Grzybowski, J., Ruddell, C. J., Tidd, D. M., & Clark, R. E. (1998). The influence of target protein half-life on the effectiveness of antisense oligonucleotide analog-mediated biologic responses. ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT, 8(4), 281-293. doi:10.1089/oli.1.1998.8.281

DOI
10.1089/oli.1.1998.8.281
Journal article

1997

Improving the molecular efficacy of antisense oligonucleotider (ODN) in chronic myeloid leukaemia

Clark, R. E., Grjsybowski, J., Giles, R. V., Spiller, D. G., & Tidd, D. M. (1997). Improving the molecular efficacy of antisense oligonucleotider (ODN) in chronic myeloid leukaemia. Experimental Hematology, 25(8), 892.

Journal article

Transplantation of antisense oligonucleotide (odn) purged autografts in chronic myeloid leukaemia (cml)

Clark, R. E. (1997). Transplantation of antisense oligonucleotide (odn) purged autografts in chronic myeloid leukaemia (cml). Experimental Hematology, 25(8), 781.

Journal article

Preclinical studies of streptolysin-O in enhancing antisense oligonucleotide uptake in harvests from chronic myeloid leukaemia patients

Broughton, C. M., Spiller, D. G., Pender, N., Komorovskaya, M., Grzybowski, J., Giles, R. V., . . . Clark, R. E. (1997). Preclinical studies of streptolysin-O in enhancing antisense oligonucleotide uptake in harvests from chronic myeloid leukaemia patients. LEUKEMIA, 11(9), 1435-1441. doi:10.1038/sj.leu.2400774

DOI
10.1038/sj.leu.2400774
Journal article

European results of matched unrelated donor bone marrow transplantation for chronic myeloid leukemia. Impact of HLA class II matching. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

Devergie, A., Apperley, J. F., Labopin, M., Madrigal, A., Jacobsen, N., Carreras, E., . . . Gratwohl, A. (1997). European results of matched unrelated donor bone marrow transplantation for chronic myeloid leukemia. Impact of HLA class II matching. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.. Bone marrow transplantation, 20(1), 11-19. doi:10.1038/sj.bmt.1700844

DOI
10.1038/sj.bmt.1700844
Journal article

Molecular status of individual CFU-GM colonies derived from chemotherapy-mobilised peripheral blood stem cells in chronic myeloid leukaemia

Broughton, C. M., Sherrington, P., Pender, N. T., & Clark, R. E. (1997). Molecular status of individual CFU-GM colonies derived from chemotherapy-mobilised peripheral blood stem cells in chronic myeloid leukaemia. GENES CHROMOSOMES & CANCER, 18(4), 292-298. doi:3.0.CO;2-W">10.1002/(SICI)1098-2264(199704)18:4<292::AID-GCC7>3.0.CO;2-W

DOI
10.1002/(SICI)1098-2264(199704)18:4<292::AID-GCC7>3.0.CO;2-W
Journal article

Molecular status of individual CFU-GM colonies derived from chemotherapy-mobilised peripheral blood stem cells in chronic myeloid leukaemia.

Broughton, C. M., Sherrington, P., Pender, N. T., & Clark, R. E. (1997). Molecular status of individual CFU-GM colonies derived from chemotherapy-mobilised peripheral blood stem cells in chronic myeloid leukaemia.. Genes, chromosomes & cancer, 18(4), 292-298. doi:3.0.co;2-w">10.1002/(sici)1098-2264(199704)18:4<292::aid-gcc7>3.0.co;2-w

DOI
10.1002/(sici)1098-2264(199704)18:4<292::aid-gcc7>3.0.co;2-w
Journal article

Treatment of chronic myeloid leukaemia in first chronic phase with idarubicin and cytarabine: mobilization of Philadelphia-negative peripheral blood stem cells.

Chalmers, E. A., Franklin, I. M., Kelsey, S. M., Newland, A. C., Clark, R. E., Sproul, A. M., . . . Tansey, P. (1997). Treatment of chronic myeloid leukaemia in first chronic phase with idarubicin and cytarabine: mobilization of Philadelphia-negative peripheral blood stem cells.. British journal of haematology, 96(3), 627-634. doi:10.1046/j.1365-2141.1997.d01-2058.x

DOI
10.1046/j.1365-2141.1997.d01-2058.x
Journal article

Bone marrow effects of anticancer therapy

Clark, R. E. (1997). Bone marrow effects of anticancer therapy. In J. W. Sweetenham, & C. J. Williams (Eds.), Supportive care of the cancer patient (pp. 3-15). London: Edward Arnold.

Chapter

Stem cell transplantation

Clark, R. E. (1997). Stem cell transplantation. In F. E. Johnson, & K. S. Virgo (Eds.), Cancer patient follow-up (pp. 504-507). St Louis: Mosby Inc..

Chapter

The follow-up of patients with lymphoma

Clark, R. E. (1997). The follow-up of patients with lymphoma. In F. E. Johnson, & K. S. Virgo (Eds.), Cancer patient follow-up (pp. 480-483). St Louis: Mosby Inc..

Chapter

1996

The influence of class II HLA type on the lymphoproliferative response of normal donors to a bcr-abl fusion peptide.

MacIntyre, A. R., Christmas, S. E., & Clark, R. E. (1996). The influence of class II HLA type on the lymphoproliferative response of normal donors to a bcr-abl fusion peptide.. Experimental hematology, 24(11), 1307-1311.

Journal article

1995

Optimization of antisense oligodeoxynucleotide structure for targeting bcr-abl mRNA.

Giles, R. V., Spiller, D. G., Green, J. A., Clark, R. E., & Tidd, D. M. (1995). Optimization of antisense oligodeoxynucleotide structure for targeting bcr-abl mRNA.. Blood, 86(2), 744-754.

Journal article

FMS mutations in patients following cytotoxic therapy for lymphoma

Baker, A., Cachia, P. G., Ridge, S. A., McGlynn, H., Clark, R. E., Whittaker, J. A., . . . Padua, R. A. (1995). FMS mutations in patients following cytotoxic therapy for lymphoma. Leukaemia Research, 19, 309-318.

Journal article

Poor cellular uptake of antisense oligodeoxynucleotides: an obstacle to their use in chronic myeloid leukaemia.

Clark, R. E. (1995). Poor cellular uptake of antisense oligodeoxynucleotides: an obstacle to their use in chronic myeloid leukaemia.. Leukemia & lymphoma, 19(3-4), 189-195. doi:10.3109/10428199509107888

DOI
10.3109/10428199509107888
Journal article

Psychosocial morbidity following bone marrow transplantation is related to previous experience of intensive therapy

Leigh, S., Burns, R., Wilson, K., & Clark, R. E. (1995). Psychosocial morbidity following bone marrow transplantation is related to previous experience of intensive therapy. Bone Marrow Transplantation, 13, 635-640.

Journal article

Psychosocial morbidity in bone marrow transplant recipients: a prospective study.

Leigh, S., Wilson, K. C., Burns, R., & Clark, R. E. (1995). Psychosocial morbidity in bone marrow transplant recipients: a prospective study.. Bone marrow transplantation, 16(5), 635-640.

Journal article

Severe hypophosphataemia during stem cell harvesting in chronic myeloid leukaemia.

Clark, R. E., & Lee, E. S. (1995). Severe hypophosphataemia during stem cell harvesting in chronic myeloid leukaemia.. British journal of haematology, 90(2), 450-452. doi:10.1111/j.1365-2141.1995.tb05172.x

DOI
10.1111/j.1365-2141.1995.tb05172.x
Journal article

Transplantation of T-lymphocyte depleted marrow with an addback of T cells.

Clark, R. E., & Pender, N. (1995). Transplantation of T-lymphocyte depleted marrow with an addback of T cells.. Hematological oncology, 13(4), 219-224. doi:10.1002/hon.2900130406

DOI
10.1002/hon.2900130406
Journal article

Transplantation of T-lymphocyte depleted marrow with an addback of T cells: Control of graft-versus-host disease with a high relapse rate

Clark, R. E., & Pender, N. (1995). Transplantation of T-lymphocyte depleted marrow with an addback of T cells: Control of graft-versus-host disease with a high relapse rate. Haematological Oncology, 13, 219-224.

Journal article

1994

Delayed commencement of granulocyte colony-stimulating factor following autologous bone marrow transplantation accelerates neutrophil recovery and is cost-effective.

Clark, R. E., Shlebak, A. A., & Creagh, M. D. (1994). Delayed commencement of granulocyte colony-stimulating factor following autologous bone marrow transplantation accelerates neutrophil recovery and is cost-effective.. Leukemia & lymphoma, 16(1-2), 141-146. doi:10.3109/10428199409114151

DOI
10.3109/10428199409114151
Journal article

Mobilisation of Ph-negative peripheral blood stem cells in CML with Idarubicin and Cytarabine

Chalmers, E. A., Franklin, I. M., Kelsey, S., Clark, R. E., Sproul, A. M., Goldstone, A. H., . . . Tansey, P. (1994). Mobilisation of Ph-negative peripheral blood stem cells in CML with Idarubicin and Cytarabine. Bone Marrow Transplantation, 14, Su, 38-41.

Journal article

The efficacy of recombinant human granulocyte colony-stimulating factor and recombinant human granulocyte macrophage colony-stimulating factor in permitting the administration of higher doses of cyclophosphamide in a doxorubicin-cyclophosphamide combination. An NSABP pilot study in patients with metastatic or high-risk primary breast cancer. National Surgical Adjuvant Breast and Bowel Project.

Mamounas, E. P., Anderson, S., Wickerham, D. L., Clark, R., Stoller, R., Hamm, J. T., . . . Bornstein, R. (1994). The efficacy of recombinant human granulocyte colony-stimulating factor and recombinant human granulocyte macrophage colony-stimulating factor in permitting the administration of higher doses of cyclophosphamide in a doxorubicin-cyclophosphamide combination. An NSABP pilot study in patients with metastatic or high-risk primary breast cancer. National Surgical Adjuvant Breast and Bowel Project.. American journal of clinical oncology, 17(5), 374-382. doi:10.1097/00000421-199410000-00002

DOI
10.1097/00000421-199410000-00002
Journal article

Thrombotic microangiopathy following bone marrow transplantation.

Pettitt, A. R., & Clark, R. E. (1994). Thrombotic microangiopathy following bone marrow transplantation.. Bone marrow transplantation, 14(4), 495-504.

Journal article

Vogt-Koyanagi-Harada syndrome complicating allogeneic bone marrow transplantation.

Pettitt, A. R., Neoh, C., Wong, S. H., & Clark, R. E. (1994). Vogt-Koyanagi-Harada syndrome complicating allogeneic bone marrow transplantation.. Bone marrow transplantation, 13(2), 225-227.

Journal article

1993

Clonal haemopoiesis following cytotoxic therapy for lymphoma.

Cachia, P. G., Culligan, D. J., Clark, R. E., Whittaker, J. A., Jacobs, A., & Padua, R. A. (1993). Clonal haemopoiesis following cytotoxic therapy for lymphoma.. Leukemia, 7(6), 795-800.

Journal article

Long-term bone marrow cultures established from bone marrow transplant recipients.

Treweeke, A. T., Hampson, J., & Clark, R. E. (1993). Long-term bone marrow cultures established from bone marrow transplant recipients.. Leukemia & lymphoma, 12(1-2), 117-122. doi:10.3109/10428199309059579

DOI
10.3109/10428199309059579
Journal article

1992

Chromosome aberrations following cytotoxic therapy in patients in complete remission from lymphoma.

White, A. D., Jones, B. M., Clark, R. E., & Jacobs, A. (1992). Chromosome aberrations following cytotoxic therapy in patients in complete remission from lymphoma.. Carcinogenesis, 13(7), 1095-1099. doi:10.1093/carcin/13.7.1095

DOI
10.1093/carcin/13.7.1095
Journal article

Isochromosome (6p) in Waldenstrom's macroglobulinemia.

White, A. D., Clark, R. E., & Jacobs, A. (1992). Isochromosome (6p) in Waldenstrom's macroglobulinemia.. Cancer genetics and cytogenetics, 58(1), 89-91. doi:10.1016/0165-4608(92)90141-t

DOI
10.1016/0165-4608(92)90141-t
Journal article

1990

Haemopoietic and molecular abnormalities in the myelodysplastic syndrome

Jacobs, A., Carter, G., Ridge, S., Hughes, D., Geddes, D., Bowen, D., . . . Padua, R. A. (1990). Haemopoietic and molecular abnormalities in the myelodysplastic syndrome. In L. Sachs (Ed.), Molecular Biology of Haemopoiesis (pp. 571-577). Andover UK: Intercept Ltd.

Chapter

RAS mutations in patients following cytotoxic therapy for lymphoma.

Carter, G., Hughes, D. C., Clark, R. E., McCormick, F., Jacobs, A., Whittaker, J. A., & Padua, R. A. (1990). RAS mutations in patients following cytotoxic therapy for lymphoma.. Oncogene, 5(3), 411-416.

Journal article

1989

Differences in bone marrow cytogenetic characteristics between treated and untreated myeloma.

Clark, R. E., Geddes, A. D., Whittaker, J. A., & Jacobs, A. (1989). Differences in bone marrow cytogenetic characteristics between treated and untreated myeloma.. European journal of cancer & clinical oncology, 25(12), 1789-1793. doi:10.1016/0277-5379(89)90349-0

DOI
10.1016/0277-5379(89)90349-0
Journal article

Posttransplantation diabetes mellitus in heart transplant recipients.

Ladowski, J. S., Kormos, R. L., Uretsky, B. F., Lee, A., Curran, M., Clark, R., . . . Hardesty, R. L. (1989). Posttransplantation diabetes mellitus in heart transplant recipients.. The Journal of heart transplantation, 8(2), 181-183.

Journal article

RAS mutations detected by PCR and specific oligonucleotide hybridisation in preleukaemia

Carter, G., Padua, R. A., Hughes, D. C., McCormick, F., Oscier, D., Clark, R. E., . . . Jacobs, A. (1989). RAS mutations detected by PCR and specific oligonucleotide hybridisation in preleukaemia. Cancer Cells, 7, 143-145.

Journal article

RAS oncogenes

Jacobs, A., Padua, R. A., Carter, G., Hughes, D., Clark, R. E., Oscier, D., . . . McCormick, F. (1989). RAS oncogenes. In D. Spandidos (Ed.), RAS oncogenes (Vol. 170, pp. 1-100). New York: Plenum Press.

Chapter

1988

13-cis-retinoic acid v placebo in myelodysplasia.

Jacobs, A., & Clark, R. E. (1988). 13-cis-retinoic acid v placebo in myelodysplasia.. Blood, 72(4), 1439-1440.

Journal article

Myelodysplastic syndrome in a kindred with ins(16) (p11.2).

Clark, R. E., Geddes, D., Whittaker, K., & Jacobs, A. (1988). Myelodysplastic syndrome in a kindred with ins(16) (p11.2).. Clinical genetics, 33(6), 418-423. doi:10.1111/j.1399-0004.1988.tb03474.x

DOI
10.1111/j.1399-0004.1988.tb03474.x
Journal article

Myelodysplastic syndrome in a kindred with ins(16)(p11.2)

Clark, R. E., Geddes, D., Whittaker, K., & Jacobs, A. (1988). Myelodysplastic syndrome in a kindred with ins(16)(p11.2). Clinical Genetics, 33, 417-422.

Journal article

1987

Effect of 13-cis-retinoic acid on survival of patients with myelodysplastic syndrome.

Clark, R. E., Jacobs, A., Lush, C. J., & Smith, S. A. (1987). Effect of 13-cis-retinoic acid on survival of patients with myelodysplastic syndrome.. Lancet (London, England), 1(8536), 763-765. doi:10.1016/s0140-6736(87)92796-6

DOI
10.1016/s0140-6736(87)92796-6
Journal article

A randomized trial of 13-cis retinoic acid with or without cytosine arabinoside in patients with the myelodysplastic syndrome.

Clark, R. E., Ismail, S. A., Jacobs, A., Payne, H., & Smith, S. A. (1987). A randomized trial of 13-cis retinoic acid with or without cytosine arabinoside in patients with the myelodysplastic syndrome.. British journal of haematology, 66(1), 77-83. doi:10.1111/j.1365-2141.1987.tb06893.x

DOI
10.1111/j.1365-2141.1987.tb06893.x
Journal article

The effect of cytosine arabinoside on CFU-GM from patients with myelodysplastic syndrome.

Bailey-Wood, R., Clark, R. E., Dallimore, C. M., & Jacobs, A. (1987). The effect of cytosine arabinoside on CFU-GM from patients with myelodysplastic syndrome.. Clinical and laboratory haematology, 9(1), 23-26. doi:10.1111/j.1365-2257.1987.tb01378.x

DOI
10.1111/j.1365-2257.1987.tb01378.x
Journal article

1986

Pathogenesis and clinical variations in the myelodysplastic syndromes

Jacobs, A., & Clark, R. E. (1986). Pathogenesis and clinical variations in the myelodysplastic syndromes. Clinics in Haematology, 15, 925-952.

Journal article

Prognostic importance of hypodiploid hemopoietic precursors in myelodysplastic syndromes.

Clark, R., Peters, S., Hoy, T., Smith, S., Whittaker, K., & Jacobs, A. (1986). Prognostic importance of hypodiploid hemopoietic precursors in myelodysplastic syndromes.. The New England journal of medicine, 314(23), 1472-1475. doi:10.1056/nejm198606053142302

DOI
10.1056/nejm198606053142302
Journal article

DNA content and cell cycle analysis of bone marrow cells in myelodysplastic syndromes (MDS).

Peters, S. W., Clark, R. E., Hoy, T. G., & Jacobs, A. (1986). DNA content and cell cycle analysis of bone marrow cells in myelodysplastic syndromes (MDS).. British journal of haematology, 62(2), 239-245. doi:10.1111/j.1365-2141.1986.tb02927.x

DOI
10.1111/j.1365-2141.1986.tb02927.x
Journal article

Pathogenesis and clinical variations in the myelodysplastic syndromes.

Jacobs, A., & Clark, R. E. (1986). Pathogenesis and clinical variations in the myelodysplastic syndromes.. Clinics in haematology, 15(4), 925-951.

Journal article

1985